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Ribosomally synthesized and post-translationally modified peptides (RiPPs) are a diverse 
and rapidly expanding class of natural products. Despite starting out as linear chains of amino 
acids, RiPP natural products acquire structural diversity ranging from small molecules like 
microcin C7 to 48-mer polytheonamides with varying post-translational modifications installed by 
biosynthetic enzymes. These conformational restrictions allow these natural products to exhibit a 
wide range of therapeutic activities like antifungal, antibacterial, allelopathic, and antiviral. 
Despite the structural and functional disparities, they all share a common feature: the presence of 
amino acid sequence in the precursor peptide called the ‘leader peptide’ that helps guide the 
biosynthetic enzymes towards the remaining precursor peptide termed the ‘core peptide’ to act on 
specific residues and install different PTMs. This leader-peptide guided biosynthetic route 
provides tremendous opportunity to bioengineer libraries of analogues of RiPPs. Exploiting this 
feature, in Chapter 2, I report my investigations on a strategy wherein by swapping the leader 
peptides from unrelated RiPP biosynthetic pathways and modifying the core peptide sequences, 
different biosynthetic enzymes can perform their characteristic chemistries on the core peptide 
residues.  
In Chapter 3, I report the design and usage of chimeric leader peptides that can be bound 
by multiple enzymes from unrelated RiPP pathways to create new-to-nature hybrid RiPPs. This 
strategy involves the combination of a cyclodehydratase with modification enzymes from different 
lanthipeptide RiPP classes. These hybrids provide insight into enzyme promiscuity and 
compatibility, and the biosynthetic order of events, and establish a general platform for the 
engineering additional hybrid RiPPs.  
 iii 
In Chapter 4, I develop two different strategies for non-proteinogenic amino acid 
incorporation in the class I lantibiotic nisin and the class II lantibiotic lacticin 481 using amber 
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Chapter 1: Gifts from Microorganisms 
 
1.1 Introduction  
Natural products (NPs) possess splendid structural, functional and chemical diversity that 
is yet to be matched by any synthetic libraries of compounds and continue to be the source of 
inspiration for novel discoveries and breakthroughs in chemistry, biology, and medicine. Their 
structures have evolved over millions of years to be extremely efficient in their tasks, be it 
housekeeping or combat against environmental agents. The history of medicine is filled with 
examples where a natural product saved thousands of lives through its medicinal properties (e.g. 
penicillin in World War II) or led to the discovery of an even more potent small molecule. And 
there is more to be discovered, uncovered and explored in this new age of natural product drug 
discovery.  
Besides the four well-established and well-researched classes of NPs, terpenoids, alkaloids, 
polyketides, and non-ribosomal peptides (NRPs), a relatively new class of NPs that has come to 
light and garnered tremendous scientific interest is the ribosomally synthesized and post-
translationally modified peptides (RiPPs).1-5 Unlike their non-ribosomal counterparts, these 
peptides do not require large, modular, multifunctional enzymes known as non-ribosomal peptide 
synthetases for installing non-proteinogenic amino acids into the peptide backbone.3, 4, 6 RiPPs 
acquire a similar extent of structural diversity as NRPs through exhaustive post-translational 
modifications (PTMs) of a ribosomally synthesized precursor peptide (see Figure 1.1).1 This 
allows RiPPs to possess a wide variety of structural features that endow them with desirable 
medicinal properties like resistance to proteolysis and a lower entropic cost of target binding.3, 5 
Therefore, not surprisingly, a plethora of RiPPs exhibit a range of activities such as antifungal, 
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Figure 1.1 Chemical structures of selected RiPP subfamily members. The second line 



































































































































































































































































































































antibacterial, allelopathic, and antiviral (see Table 1.1).1, 3 Compared to ~3000 nucleotides required 
to add/change a single amino acid in the NRP system, RiPPs only need three nucleotides, and it is 
due to this enormous advantage that the ribosomal world has an edge over the non-ribosomal one 
with respect to chemical research and drug discovery.4 Additionally, through the cost reduction of 
genome sequencing techniques and the advances made in bioinformatics for more accurate protein 
function annotation,7 more and more RiPP gene clusters with potentially new PTMs are being 
uncovered,8 and new connections are being established between classes of enzymes previously 
thought to be unrelated, thereby paving the way for a better understanding of the evolution of 
biology in the microbial world. 
 
Table 1.1 Selected RiPPs with proven or potential applications as drugs.3 

































Microviridin Microcystis viridis 1990 Serine protease 
inhibitor 
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1.2 Ribosomally synthesized and post-translationally modified peptides (RiPPs) 
To date, more than twenty RiPP families (MW < 10 kDa) are known, which are subdivided 
into members according to their PTMs.1 Typically, RiPP biosynthesis starts with the translation of 
a precursor peptide on the ribosome (Figure 1.2). The precursor peptide contains two distinct 
regions: a leader peptide and a core peptide. In most RiPPs, the leader peptide is attached to the 
N-terminus of the core peptide and is usually important for recognition by most of the biosynthetic 
enzymes for installing primary PTMs, and for export.17 However, in certain cases, the leader 
peptide is found to be appended to the C-terminus of the core peptide and is called a “follower” 
peptide.18-20 After translation, the biosynthetic enzymes recognize and bind to the leader peptide, 
and install different class-defining PTMs (summarized in Table 1.2) on specific residues of the 
core peptide. The modified peptide then undergoes proteolytic cleavage to remove the leader 
peptide and the resulting mature RiPP is transported outside the host cell. In certain gene clusters, 
besides the leader peptide-dependent biosynthetic enzymes, certain secondary enzymes are present 
that can act on the core peptide independent of the leader peptide and install chemical 
functionalities that are crucial for the bioactivites.21 Despite playing a crucial role in biosynthesis 
as a recognition element, the term ‘leader peptide’ is loosely defined for classification purposes 
since we cannot negate that the recognition motif can extend well into the core peptide as well. So, 
for all purposes, ‘leader peptide’ is the portion of precursor peptide that is cleaved off to form a 
mature RiPP natural product, and the part that is retained in the mature product constitutes the 
‘core peptide’.  
This leader-peptide guided strategy for the biosynthesis of such a diverse class of RiPP 
natural products sheds light on the observation of several precursor peptides with practically 
similar leader peptides but hypervariable core sequences that can be present in the same 
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Figure 1.2 General biosynthetic pathway for RiPPs. The precursor peptide contains a core 
region that is transformed into the mature product. Many of the posttranslational modifications are 
guided by the leader peptide and the recognition elements in the biosynthetic enzymes.  
 
 
biosynthetic gene clusters.22 This finding speaks volumes about the inherent promiscuity of RiPP 
biosynthetic enzymes and the overall ease of evolution in nature or genetic engineering in a 
laboratory setting, for creating structural analogs at a low genetic cost.  
The remainder of this chapter will focus on two subfamilies of RiPPs: lanthipeptides and 







Table 1.2 Summary of all known RiPPs subfamilies.5, 23-25 
RiPPs subfamily Defining PTM 
Lanthipeptides Lan and/or MeLan thioether bis-amino acids 
Linaridins dehydroamino acids but lacking Lan/MeLan 
Proteusins linear peptides containing D-amino acids and C-methylations 
Linear azol(in)e-containing 
peptides 
linear peptides containing (methyl)oxazol(in)e or/and thiazol(in)e 
heterocycles 
Cyanobactins N-to-C macrocyclic peptides produced by cyanobacteria 
sometimes further decorated with azole(in)es and/or prenylations 
Thiopeptides a central six-membered nitrogen-containing ring 
additional PTMs include dehydrations and cyclodehydrations 
Bottromycins an N-terminal macrocyclic amidine 
a C-terminal follower peptide instead of N-terminal leader peptide 
Microcins produced by members of the Enterobacteriaceae family 
include some members of the lasso peptide and LAP families 
Lasso peptides an N-terminal macrolactam with the C-terminal tail threaded through the 
ring 
Microviridins lactones made from Glu/Asp and Ser/Thr side chains and lactams made from 
Lys and Glu/Asp residues 
Sactipeptides intramolecular thioether linkages between Cys side chains and α-carbons of 
other amino acids 
Bacterial head-to-tail cyclized 
peptides 
N-to-C cyclized peptides differing from cyanobactins in the biosynthetic 
machinery employed for macrocyclization 
Amatoxins and Phallotoxins N-to-C cyclized peptides produced by fungi 
Cyclotides N-to-C cyclized peptides produced by plants containing a cysteine knot 
composed of three disulfides 
Orbitides N-to-C cyclized peptides produced by plants lacking disulfides 
Conopeptides venom peptides produced by snails; the degree and type of PTM varies 
Glycocins glycosylated antimicrobial peptides 
Autoinducing peptides peptides containing a cyclic ester or a thioester 
Methanobactin peptidic chelators used by methanotrophic bacteria 
Streptide a Trp-to-Lys carbon-carbon crosslink 
Thioamides peptides containing thioamide linkages installed post-translationally 
Pyrroloquinoline quinone (PQQ), 
pantocin, and thyroid hormones 
small molecules generated from the post-translational modification of a 
precursor peptide or protein 
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Table 1.2 (cont.)  
Phomopsins 13-member macrocyclic ring formed by an ether bridge linking an Ile 
residue to the phenyl ring of a Tyr and contain dehydroamino acids and no 
proteinogenic amino acids 
Ustiloxins 13-member macrocyclic ring formed by an ether bridge linking an Ile 
residue to the phenyl ring of a Tyr and contain proteinogenic amino acids 
N-methylated peptides N-methylation of the peptide backbone by a methyltransferase domain 
encoded within the leader sequence of the precursor protein 
 
1.3 Lanthipeptides 
Lanthipeptides, for example nisin (Figure 1.1), are characterized by the presence of the 
thioether containing amino acids called lanthionine (Lan) or 3-methyllanthionine (MeLan) (Figure 
1.3). These characteristic PTMs are installed in two steps biosynthetically. In the first step, selected 
Ser/Thr residues in the core region of a precursor peptide, called LanA, are dehydrated to 2,3-
didehydroalanine (Dha) and (Z)-2,3-didehydrobutyrine (Dhb), respectively (Figure 1.3).1, 2 In the 
second step, specific Cys thiols attack the unsaturated amino acids in a Michael-type addition 
reaction to form (Me)Lan.1, 2 Originating from an anti-addition of Cys on Dha or Dhb, the 
stereochemistry depends on whether the thiol attacks from above or below the plane of the double 
bond to generate: (2S,6R)/(2R,6R)-Lan or (2S,3S,6R)/(2R,3R,6R)-MeLan. The (2S,6R)-Lan and 
(2S,3S,6R)-MeLan are more commonly present (also known as the DL isomers; D configuration 
at the former Ser/Thr and L configuration at the former Cys).1, 2, 5 The (2R,6R)-Lan and 
(2R,3R,6R)-MeLan rings (also known as the LL isomers) are formed only when the core peptide 
has a Dhx-Dhx-Xxx-Xxx-Cys motif (Dhx represents Dha or Dhb and Xxx represents amino acids 
other than Ser, Thr and Cys) since two consecutive dehydroamino acids impose conformational 
restrictions that disfavor the Si face attack of Cys.26, 27 This observation was of special interest 
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since it showed that the substrate, and not the enzyme, determines the outcome of the reaction 
which happens rarely in enzymatic reactions. 
 
Figure 1.3 Biosynthetic route for the formation of the most common post-translational 
modifications found in lanthipeptides. Depending upon the face from which Michael-type attack 
of Cys thiols takes place, two stereochemistries for the thioether rings are possible as shown. 
 
 
Lanthipeptides are classified into four categories based on the mechanism of installation of 
the thioether rings and the number of enzymes involved in each step. Class I lanthipeptides are 
produced by the action of two enzymes: a lanthipeptide dehydratase (LanB) and a lanthipeptide 
cyclase (LanC).1, 2 The mechanism for dehydration of Ser/Thr by LanB involves an unanticipated 
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co-substrate: glutamyl-tRNAGlu. Studies carried out on the lanthipeptide dehydratase NisB 
involved in nisin biosynthesis revealed that dehydration proceeds through glutamylation of Ser/Thr 
residues within the precursor peptide NisA (Figure 1.4).28, 29 In the proposed mechanism,28, 29 upon 
deprotonation, the Ser/Thr side chain attacks the α-carbon of glutamate bound to tRNAGlu, thereby 
eliminating tRNAGlu. The intermediate then collapses with the abstraction of the α-H of the 
glutamylated Ser/Thr resulting in Dha or Dhb, and glutamate. LanB does not aminoacylate tRNA 
itself but instead uses the cellular pool of glutamyl-tRNAGlu for the activation of Ser/Thr. Structural 
characterization of NisB demonstrated that the protein consists of two domains: one at the N-
terminus that catalyzes glutamylation and the other at the C-terminus that facilitates glutamate 
elimination. The core peptide moves between the two domains during dehydration.28 The 
identification of glutamyl-tRNAGlu as the co-substrate took more than 25 years since the nisB gene 
was sequenced primarily owing to the fact that NisB shares no significant structural homology 
with tRNA synthetases or other enzymes involved in secondary metabolism that use 
aminoacylated-tRNAs (aa-tRNAs) like cyclodipeptide synthetases.30-32 The lack of such homology 
however hints towards a new mode of interaction between class I lanthipeptide dehydratases and 
aa-tRNAs.  
In class II lanthipeptides, the thioether rings are installed by a bifunctional lanthionine 
synthetase, LanM, containing an N-terminal dehydratase domain and a C-terminal cyclase 
domain.1 The dehydrations in class II lanthipeptides are carried out in two steps as well: the ATP-
dependent phosphorylation of Ser/Thr residues followed by phosphate elimination (Figure 1.4).33 
The N-terminal domains share homology with PoyF dehydratase involved in the biosynthesis of 
polytheonamides,34 and the C-terminal domains are homologous with the class I LanC cyclases. 




Figure 1.4 Proposed dehydration mechanism employed by class I lanthipeptide dehydratases 
and class II–IV lanthionine synthetases. 
 
two Cys ligands at the active site.35-38 However, the cyclase domain of the class II lantibiotic 
synthetase ProcM that modifies twenty nine different precursor peptides has three Cys ligands at 
its active site and forms a distinct clade in the phylogenetic tree of class II LanM synthetases.38 
This difference is speculated to cause two main rifts from the general trend of cyclase activity. 
Firstly, a His ligand at the active site can act as the base that deprotonates the α-proton of the 
thioether rings causing ring opening.39 Therefore, NisC and class II lanthipeptide synthetase 
HalM2 both have been shown to be capable of opening up multiple rings under the conditions of 
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catalysis, even though only the ring-closed peptide is observed at equilibrium (Figure 1.5).39 In 




Figure 1.5 Cyclizations catalyzed by both NisC and HalM2 are reversible, as shown with α-
D-labeled modified NisA and modified HalA2. D/H exchange in α-D-labeled substrate could 
occur either by a deprotonation/reprotonation mechanism (route 1) or by a reversible cyclization 
mechanism (route 2). The reversibility of cyclization was confirmed for α-D-labeled mHalA2 and 
mNisA by trapping of the ring-opened species by conjugate addition to NEM.39 
 
 
Secondly, this difference in the identity of the active site ligands aids in the promiscuous 
activity of ProcM since the presence of three thiolate ligands increases the positive charge density 
on the zinc ion, thereby, increasing the enzyme reactivity.40 Surprisingly, this does not come at a 
cost of low substrate selectivity since ProcM essentially makes single products of a specific ring 


















































Route 1: Exchange of α-D with solvent
Route 2: Opening of thioether ring
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kinetic control, and therefore, high regioselectivity of product formation is governed by the 
selectivity of the initially formed ring.40  
The recently reported crystal structure of the class II lanthionine synthetase CylM, involved 
in cytolysin biosynthesis, revealed for the first time that structurally the N-terminal domain of 
LanM resembles the catalytic unit of eukaryotic lipid kinases despite having no sequence 
homology with it.41 Co-crystallization experiments with AMP and mutagenesis data revealed that 
the kinase active site and the phosphate-elimination active site are overlapping, which suggests 
that these enzymes carry out phosphorylation and phosphate elimination in a processive manner.41 
This hypothesis is further supported by the dependence of the phosphate elimination on ADP, and 
the absence of detectable phosphorylated precursor peptide intermediates.41, 42  
So far we have seen two different mechanisms and two different routes of evolution for 
enzymes involved in the formation of (Me)Lan rings. A third route is found to be adopted by class 
III and IV synthetases. These are trifunctional enzymes composed of a central Ser/Thr kinase 
domain, an N-terminal phosphoSer/phosphoThr lyase domain, and a C-terminal cyclization 
domain.13, 43-45 The dehydration occurs through a phosphate intermediate like in class II, however, 
the activation of the Ser/Thr –OH group with ATP, and the elimination of phosphate group from 
the intermediate occurs in two separate domains, resembling class I dehydratase. Although C-
terminal cyclization domains display sequence homology to each other as well as to the LanC 
proteins, three metal binding residues that are fully conserved in class I, II, and IV cyclases are 
absent in the class III cyclization domains. This abnormality is suspected to be responsible for the 
formation of carbacyclic structures termed labionin by some of the class III enzymes.12 Labionins 
are formed by a second Michael-type addition of the enolate intermediate formed upon initial 
thioether ring formation into a second Dha.12  
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Some RiPPs comprise of D-amino acids, such as the two component lanthipeptides 
carnolysin and bicereucin that contain D-aminobutyrate (D-Abu) while the latter also contains D-
alanine (D-Ala).46, 47 The mechanism involves the reduction of Dha to D-Ala and Dhb to D-Abu,46, 
47 and the enzymes involved can be used to make more structurally diverse analogs.  
 
1.4 Linear azole-containing peptides (LAPs) 
  The LAPs are a heterogeneous subclass of RiPPs with the characteristic feature being the 
presence of azole or azoline heterocycles within a linear peptide, unlike macrocyclized RiPPs like 
cyanobactins and thiopeptides.1, 8 As for all RiPPs, their biosynthesis initiates with the translation 
of a precursor peptide with a N-terminal leader region and C-terminal core peptide. The 
biosynthetic machinery involved are classified as protein B, a flavin-dependent dehydrogenase, 
protein C which is a member of the E1-ubiquitin activating (E1-like) superfamily, and a protein D 
(cyclodehydratase from the YcaO superfamily).1, 8 In certain gene clusters, genes for protein C and 
D are fused together.8 Upon binding to the leader peptide, the CD enzyme complex carries out 
ATP-dependent cyclodehydration of specific Ser, Thr or Cys residues to form azolines with the 
removal of water from the carbonyl group of the preceding amide, giving rise to an azoline 
heterocycle.1, 8, 48 In the next step, protein D carries out the oxidation of azolines to azoles.1, 8  
The first conclusive proof for these previously unknown PTMs was obtained in 1996 when 
the in vitro reconstitution of the biosynthetic enzymes of microcin B17 was reported by Walsh and 
coworkers.49 However, at that time only the dehydrogenase was correctly assigned owing to the 
yellow color from binding to its co-factor, flavin mononucleotide.50 It has been proposed to 
perform the dehydrogenation via an E-2 mechanism involving a conserved Lys-Tyr motif,49, 51 
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which likely deprotonates the Cα of the azoline followed by a hydride transfer resulting in azole 




Figure 1.6 Plausible mechanism for the dehydrogenation of methyloxazoline catalyzed by B 
enzymes. The conserved Lys-Tyr motif is likely involved in deprotonating the Cα of the azoline, 
which is followed by hydride transfer. 
 
For more than a decade, the specific roles that proteins C and D were playing could not be 
easily distinguished primarily since very few LAPs gene clusters had been reported then, and most 
of the cyclodehydratases available were dependent on other proteins in the complex for activity. 
In 2012, with the in vitro reconstitution of the Balh cyclodehydratase from Bacillus sp. Al Hakam, 
the Ycao protein, BalhD, and not BalhC was shown to carry out ATP hydrolysis.48 The exact role 
played by the protein C still remains elusive although it has been proposed to act as a scaffolding 
or docking protein.30 The last and perhaps the most important piece of the puzzle was to determine 
the mechanism of azoline formation thereby determining the role of ATP in the reaction. Two 
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different mechanisms had been proposed48, 52: 1) direct activation wherein the phosphate group of 
ATP is directly added to the heterocyclized intermediate, so as to act as a leaving group (Pi) for 
elimination (Figure 1.7), or 2) ATP acts as an allosteric regulator for the enzyme, and the active 
conformation of the enzyme is adopted upon ATP hydrolysis. Through isotope labelling studies in 
18O labelled water, it was shown that no 18O was incorporated in the free phosphate released upon 
ATP hydrolysis.14 This result supported the direct activation since the second mechanism proposed 
would involve the attack of bulk water, labelled water in this case, and result in the γ-phosphate 
being labelled upon release. The direct activation mechanism garners special interest since the 
YcaO protein hydrolyzes the stable and relatively inert amide bond in the peptide backbone for 
heterocyclization. More insights into this mechanism and protein structure can open doors for the 







Figure 1.7 Proposed mechanisms for azoline biosynthesis by YcaO domains. Direct activation 
suggests the incorporation of phosphate(s) directly into the heterocyclized intermediate, providing 




The 1945 Nobel Prize in Physiology or Medicine to Sir Alexander Fleming, Ernst B. Chain, 
and Sir Howard Florey for the discovery of penicillin and the 1952 award to Selman A. Waksman 
for the discovery of streptomycin marked the advent of the Golden Age of natural products drug 
discovery. In these celebrated years, several breakthrough discoveries were made, the most 
prominent ones resulting in the 2015 Nobel Prize to William C. Campbell and Satoshi Omura, for 
the discovery of the microbial natural product avermectin and to Youyou Tu for the discovery of 
the plant natural product artemisinin. Derivatives of avermectin have high activity against 
onchocerciasis and lymphatic filariasis,53, 54 and artemisinin is used for the treatment of malaria.55 
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However, it has been ~35 years since the avermectin and artemisinin families of drugs were first 
introduced as human therapeutics and unfortunately resistant strains have started to slowly evolve 
against them.53, 56 While developing microbial drug resistance is inevitable,57 this fast-rising tide 
can be curbed with a combination drug therapy, new use of known NP-based drugs (since NPs are 
not designed as mechanism based drugs and often interact with multiple biological targets),58-61 
and/or with discovery of new drugs.  
The RiPP class of natural products with their novel chemical scaffolds and diverse 
functionalities provide a unique platform to leap further into discovery and development of 
paradigm-changing drug molecules. Total synthesis of these NP and their analogs for structure-
activity relationship (SAR) studies is not profitable due to their complex structures. However, 
RiPPs biosynthetic systems do a phenomenal job in reaching this goal. Additionally, from a 
bioengineering perspective, the combinatorial nature of RiPP biosynthesis makes them more 
amenable for engineering vast libraries of derivatives and scanning for new bioactive molecules. 
There are multiple ways to approach this task. First, directed evolution through the use of a 
randomized library of core peptides in phage or yeast display can help identify mutants with 
desired activities.62, 63 Second, incorporation of unnatural amino acids using amber suppression 
strategies can not only aid in making a more potent derivative but also in mode of action studies 
through labeling with fluorescent or cross-linking tags.64-68 Third, the leader-peptide guided feature 
of RiPPs biosynthesis can be put to task in combining different enzymes to create novel scaffolds.17 
Fourth, alternative to the in vivo approaches, in vitro biosynthesis with reconstituted enzymes has 
resulted in promising leads in certain examples.13, 69, 70 Moreover, studies where the leader peptide 
can be used in trans to the core peptide,71, 72 or is fused to the biosynthetic enzyme,73, 74 has vast 
potential since it eliminates the need for difficult-to-synthesize long precursor peptides. Last, new 
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compounds can be discovered by characterizing the vast number of RiPP gene clusters that are 
being reported every day in the databases.7, 75 Two of these strategies have been explored in the 
following chapters. Chapter 2 and 3 describe leader peptide-guided bioengineering strategies that 
enable recognition and processing by multiple enzymes from unrelated RiPP pathways to create 
new-to-nature hybrid RiPPs. And, Chapter 4 presents methodologies for the production of 
analogues of two lantibiotics, belonging to different classes, that contain non-proteinogenic amino 
acids using amber stop codon suppression technology. 
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Chapter 2: Leader-Peptide Guided Generation of Non-Natural Hybrid RiPP Products - 
Swapping the Leader Peptide Strategy 
 
2.1 Introduction 
As mentioned in Chapter 1, since the RiPP class of natural products is synthesized on the 
ribosome as a precursor peptide, it provides a relatively easy way to bioengineer new natural 
product analogs endowed with new or an improved range of activities such as antifungal, 
antibacterial, allelopathic, and antiviral.1-4 There have been several reports wherein through site-
directed mutagenesis, or stop codon suppression strategies, the core peptide sequence was 
engineered to biosynthesize new analogs.5-8 However, in this and the next chapter, we focused on 
the role of leader peptide during biosynthesis. A decade ago, the role of the leader peptide during 
biosynthesis was poorly understood, but through the elucidation of the mechanism of installation 
of key post-translational modifications (PTMs) in RiPP natural products and the availability of 
crystal structures of precursor peptides bound to biosynthetic enzymes, the community has made 
spectacular progress.2, 9-17 Among the many functional roles proposed for the leader peptide, the 
most prominent ones suggest they serve 1) as a means of protection for the native producer since 
it greatly reduces or abolishes antimicrobial activity of the mature RiPPs as long as it is bound to 
it, 2) as a recognition element for the secretion of secondary metabolites, 3) as an allosteric agent 
in facilitating the biosynthetic enzyme to adopt an active conformation for catalysis, and most 
importantly for this work, 4) as a guiding tool for these enzymes to act on specific residues 
following the leader peptide.1, 3 It is this last feature, the leader peptide-directed installation of a 
myriad of PTMs of the RiPPs class, that we sought to better understand and exploit for 
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bioengineering of a new class of hybrid RiPP natural products with a mix-and-match of different 
biosynthetic enzymes and their corresponding PTMs. 
There have been reports showcasing the ability of leader peptides to direct its respective 
enzymes to modify non-natural cargos attached. For instance, the nisin biomachinery has been 
widely used to modify core peptides derived from other lanthipeptide and non-lanthipeptide related 
sequences attached to the NisA leader peptide in Lactococcus lactis.18-23 The versatility of the 
biomachinery was exploited to improve the properties of pharmaceutically relevant peptides in 
vivo.20, 21 However, our goals were to establish methodology that would allow installation of not 
just PTMs belonging to one class, but to combine PTMs from different classes, and therefore, truly 
make a new, hybrid, non-natural class of RiPP. 
Because of the impressive progress made in the field of genome mining, tens of thousands 
of bacterial genomes have been sequenced, and this flood of genetic information is waiting to be 
tapped for its full potential to be realized. Besides academic curiosity, the ultimate goal for 
studying these genomes and their constituent gene clusters is for synthetic biology to be viewed 
with equal, if not higher, applicability than synthetic organic chemistry in the sheer ease and 
potential to create complicated, chemically diverse molecules for the pharmaceutical, food, 
cosmetics, or electronic industries. Realization of this goal would require, at its foundation level, 
a platform to perform combinatorial biosynthesis and a better understanding of the very basal 
requirements of enzymes to be able to efficiently work with each other in a plug-and-play fashion. 
In most well-studied RiPP gene clusters, the recognition motifs in the leader peptide 
responsible for binding to the biosynthetic enzymes have been identified,2 however this is not true 
for the majority of cases reported in GenBank. So, through our efforts, we aimed to establish a 
general strategy to achieve this hefty task of combinatorial biosynthesis of new, conformationally 
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restrained and pharmacophore-rich products that expand the current proteinogenic repertoire using 
known examples of RiPP gene clusters as model systems. 
 
2.2 Sortase-mediated swapping of leader peptides 
 Given the promiscuity of RiPP modifying enzymes and their clearly defined recognition 
sequences, it would seem straightforward to engineer modifying enzymes from unrelated 
biosynthetic pathways into the same pathway, but at the start of these studies, this strategy had yet 
to be achieved in the laboratory. Since the leader peptide holds the key in the recognition by 
modification enzymes and the subsequent modification of the core peptide, we envisioned a 
platform wherein different leader peptides from different biosynthetic pathways could be 
chemically attached to the same core peptide, and then the latter could be modified by respective 
biosynthetic pathways, thereby creating a new class of hybrid RiPP products. From a practical 
standpoint, there are three main considerations to be made: 1) a facile method is required to cleave 
the first leader off the core peptide modified by the first set of biosynthetic enzymes, and then a 
method is needed to attach a new leader peptide onto the modified core, 2) the sequence of the 
core peptide should include specific native motifs (derived from the native sequence) that would 
tolerate catalysis by not just one but all enzymes used in the strategy, and 3) the promiscuity of the 
biosynthetic enzymes in the later stages should allow a partially modified core to be accepted as a 
substrate despite having  never-seen-before modifications. With their native leader peptides as well 
as short recognition sequences in the core peptides, the modifying enzymes were anticipated to 
bind to their respective recognition regions in the core peptides and sequentially install 
posttranslational modifications. Importantly, these modifications, in principle, can be rationally 
chosen and do not need to occur together in nature.  
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2.3 Design strategy 
 To test this strategy, we chose to create a hybrid of the lanthipeptide lacticin 481 and the 
microcin B17. Lacticin 481 is a class II lantibiotic that is acted upon by one bifunctional 
lanthipeptide synthetase enzyme, LctM.3 During the biosynthesis of lacticin 481, LctM performs 
both dehydrations and cyclizations on its precursor peptide LctA (Figure 2.1).3 The enzyme first 
phosphorylates the Ser/Thr targeted for dehydration, and then eliminates the phosphate to produce  
 
Figure 2.1 Biosynthesis of the class II lantibiotic lacticin 481. LctM dehydrates Ser and Thr 
residues in the core peptide of LctA, and catalyzes Michael type addition of Cys to Dha and Dhb. 
Next, LctT removes the leader peptide. Although it is drawn that cyclizations commence after all 
dehydrations are complete, the two can proceed alternately. The chemical structures for Dha, Dhb 




the dehydro-amino acids (dehydroalanine, Dha and dehydrobutyrine, Dhb). A separate active site 
catalyzes the Michael-type addition of Cys residues to the dehydro amino acids to form lanthionine 
and methyllanthionine.3 
 From previous studies investigating the biosynthesis of lacticin 481, we gathered the 
sequence and position dependence of dehydration activity of LctM: the presence of flanking Gly 
residues around a Ser prevents its dehydration by LctM, and LctM-catalysed dehydration is 
dependent on the distance to the leader peptide (Table 2.1), as has been reported for several other 
RiPP biosynthetic enzymes.24, 25 Utilizing this information, we hypothesized that the first few 
residues of the LctA core peptide act as a spacer, and can therefore be substituted with a recognition 
motif derived from the core peptide for a different modification enzyme, specially one having 
modifiable residues surrounded by Gly residues. This requirement led us to microcin B17, which 
has a spacer region between leader and core peptides that is rich in Gly, and the common 





















Table 2.1 Sequence and position dependence of dehydration by LctM.  A concise summary of 
findings about the extent of dehydration of different LctA mutants upon being modified by 
LctM.24, 25 
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 Microcin B17 is a potent inhibitor of DNA gyrase and was the first post-translationally 
modified peptide antibiotic for which the biosynthesis was reconstituted in vitro.27, 28 Its 
biosynthesis involves modification of the precursor peptide McbA by the ternary complex formed 
by its biosynthetic enzymes. The complex includes a cyclodehydratase McbD that along with a 
scaffolding/regulatory protein McbC generates oxazoline and thiazoline structures from Gly-Ser 
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and Gly-Cys sequences in an ATP-dependent fashion, respectively. The complex also contains a 
flavin-dependent dehydrogenase that oxidizes these intermediates to oxazoles and thiazoles.28, 29 
Through photocrosslinking experiments, it has been concluded that McbD is crucial for binding to 
the leader peptide of McbA.30 Recently, using substrate analogs and isotopic labeling studies, 
Mitchell and co-workers showed that the D protein is involved in directly phosphorylating peptide 
amide backbone using ATP resulting in the formation of a phosphorylated 
hemiorthoamide intermediate which upon collapse results in the formation of an azoline moiety.29 
 Studies carried out by Walsh and co-workers in understanding the biosynthetic pathway of 
microcin B17 in the late 1990s showed that 1) the directionality of microcin B17 biosynthetic 
enzymes is from N- to C- terminus, 2) a ten-Gly residue long region between the leader peptide 
and the first modified Ser in the core peptide is a spacer since it helped maintain appropriate spatial 
distance between the binding and catalytic sites of the enzyme complex, and 3) the spacer region 
can be truncated from ten Gly residues to three Gly residues without affecting the binding 
affinity.26, 28, 30 Based on these observations, we chose a seven-residue motif ‘GGGGSCG’ from 
the beginning of the core peptide of McbA to be included in our hybrid core. Additionally, since 
lacticin 481 has its post-translational modifications concentrated in the C-terminus, we 
hypothesized that there would be little perturbation in binding of the McbBCD enzymes to the 





Figure 2.2 Biosynthesis of linear azol(in)e containing peptide, microcin B17.  (A) McbCD  
complex acts on Gly-Ser and Gly-Cys motifs in the precursor peptide McbA in the first step, which 
is followed by dehydrogenation performed by flavin-dependent McbB to form oxazole and 
thiazole functionalities. (B) Reactions for generation of oxazol(in)e and thiazol(in)e motifs.  
 
 The last task in this design strategy was to find a suitable means to swap the two leader 
peptides. In most of the class II lantibiotic precursor peptides, the C-terminus of the leader peptide 
is Gly rich1 and there is only one well-studied promiscuous enzyme that can perform ligation of 
Gly rich peptides: sortase A from Staphylococcus aureus.31-34 Sortases are membrane-associated  
transpeptidases that anchor proteins on the cell wall of Gram-positive bacteria as shown in Figure 





Figure 2.3 Schematic representation of how proteins are anchored to the cell wall via sortase 
in Gram-positive bacteria.34 Sortase A is a calcium-assisted transpeptidase that binds surface 
proteins to the peptidoglycan cell wall of Gram-positive bacteria. In the first step, sortase A 
identifies its recognition motif, LPXTG, in the incoming protein and cleaves the peptide bond 
between Thr and Gly residues through the attack of active site Cys and forms an enzyme-bound 
intermediate. This is followed by the amino group of N-terminus Gly of peptidoglycan precursor 
attacking the carbonyl group of thioester intermediate, thereby releasing the enzyme and anchoring 
the protein onto the cell surface. 
 
sortase: Leu-Pro-Xxx-Thr-Gly (LPXTG, where X is any amino acid and Gly cannot be a free 
carboxylate), at or near their C-terminus. Upon recognition, the bond between the Thr and Gly 
residues is cleaved by active site Cys of sortase A thereby forming an acyl-enzyme intermediate. 
Then, this intermediate is resolved by nucleophilic attack by the free amino group of the cell wall 
precursor lipid II. This lipid II-linked protein conjugate is incorporated during cell wall synthesis 
and consequently the protein is displayed at the surface. 
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 N-terminal labeling via sortase A requires: 1) a display of 1-5 Gly residues at the N-
terminus of a peptide, 2) the recognition motif LPXTG at the C-terminus of the other peptide 
(Figure 2.4).33, 34 Therefore, in our strategy, we envisioned to ligate the second leader peptide with 
an LPETG motif at the C-terminus to the core peptide with Gly residues at the N-terminus as 






Figure 2.4 N-terminal labeling via sortase A. Specific to our system, the sortase-mediated 
ligation requires a) McbA leader with C-terminal LPXTG motif provided it is followed by at least 
one amino acid and b) a ligating partner with two-to-five Gly residues at the N-terminus, i.e., 
LctM-modified hybrid core peptide with leader peptide cleaved.  
 
 
2.4 Results and discussion 
2.4.1 Modification of LctA leader-hybrid core with LctM and subsequent proteolytic 
removal of the leader peptide 
 As per the design strategy (Figure 2.5), the McbA core motif GGGGSCG was substituted 
in place of residues from positions 1-5 of the LctA core to obtain a hybrid core peptide with 
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sequences favorable for both LctM and McbBCD to act upon. In order to cleave off the LctA leader 
after LctM-catalyzed modifications had been installed, an Ala–1Glu mutation was introduced 
since previous reports had shown the –1 position of LctA to be highly amenable for substitution 
without affecting LctM catalysis.35 As diagrammed in Figure 2.5, the hybrid peptide was tested by 
expressing His-tagged hybrid peptide and LctM in Escherichia coli (see Table 2.3 for plasmids). 
The modified peptide was affinity purified, and analyzed via matrix-assisted laser desorption 
ionization time of flight mass spectrometry (MALDI-TOF-MS). A mixture of products was 
observed, with the most processed one being three-fold dehydrated. Even upon increasing the 
number of copies of the gene encoding LctM from one to three, the extent of dehydration did not 



















Figure 2.5 Schematic depicting the strategy for sortase-mediated swapping of leader peptides 
to create a library of hybrid RiPPs. The figure details the three-step approach starting with 
LctM-catalyzed modification of the hybrid core attached to the LctA leader peptide. After the 
modification, the leader peptide is cleaved off. In the second step, sortase A ligates the hybrid core 
with Gly residues at the N-terminus with the McbA leader peptide terminating with the LPETGG 
motif. The final step involves the installation of oxazole and thiazole onto the hybrid core attached 
to the McbA leader peptide in a McbBCD assay.  
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Figure 2.6 MALDI-TOF MS spectrum of His-tagged LctA/A-1E/GGGGSCG/N15R modified 
by two/three copies of lctM in E. coli. The N15R mutation was introduced to improve solubility.36 
Despite increasing the number of copies of lctM expressed in E. coli, the 4-fold dehydrated peptide 
was not obtained as the major product. m/z calculated for [M+H]+ peak for 3-fold dehydrated 
peptide = 7496.29, m/z observed for [M+H]+ peak for 3-fold dehydrated peptide = 7496. 
 
 
 Taking inspiration from a previously reported LctA mutant,25 wherein residues were 
inserted in between the first half of the LctA core, the GGGGSCG motif was inserted between 
Lys1 and Gly2. This His-tagged hybrid peptide upon co-expressing with a single copy of lctM 
generated a fully modified peptide with the expected loss of four water molecules (Figure 2.7). 
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Proteolytic cleavage with LysC followed by HPLC purification afforded the LctM-modified core 
peptide with four Gly residues at the N-terminus. 
 
 
Figure 2.7 MALDI-TOF MS spectrum of His-tagged LctA/K1G2insGGGGSCG/N22R/F28H 
peptide modified by expressing a single copy of LctM in E. coli. The N22R and F28H mutations 
were introduced to improve solubility.36 By inserting the McbA core-derived ‘GGGGSCG’ motif 
between K1 and G2 residues of LctA core peptide instead of subsitutuing the first seven residues 
of LctA core with that motif, a single copy of lctM efficiently dehydrated the four dehydratable 
residues in the hybrid core. m/z calculated for [M+H]+ peak for 4-fold dehydrated peptide = 
7796.57, m/z observed for [M+H]+ peak for the labeled 4-fold dehydrated peptide = 7796. 
 42 
2.4.2 Sortase-Tag Expressed Protein Ligation (STEPL)33 for attaching the McbA leader 
peptide onto the LctM-modified core peptide 
 For sortase-mediated ligation to work, the STEP ligation strategy33 involved attaching the 
His-tagged catalytic unit of sortase A onto the McbA leader peptide separated by the recognition 
motif of sortase LPETGG, and a linker as shown in Figure 2.8. During the affinity purification, 
the His-tagged fused protein in the cell lysate would stay bound to the Ni beads. After washing 
and incubating with a peptide with Gly residues at the N-terminus and calcium ions, the sortase-
tagged McbA leader would form a binary complex with the ligating partner. After the ligation, the 
ligated product would not be bound to the Ni beads and elute. 
 
 
Figure 2.8 Scheme for STEPL. An additional motif from spacer region of McbA, VGIGG was 
introduced after the McbA leader peptide to maintain the distance between the McbBCD 
recognition site on McbA leader peptide and the first residue in the core peptide that is modified. 
The Histagged-catalytic unit of sortase A is fused to this McbA leader with C-terminal LPETG 
motif. The fused protein is expressed and loaded on a nickel column. Upon addition of calcium 
and hybrid core peptide with N-terminal glycine residues, the sortase enzyme catalyzes peptide 
ligation, resulting in its elution from the column.  
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 To optimize the ligation conditions, a short three-residue test peptide, GGG, was used at 
different concentrations while varying the concentration of CaCl2 and the incubation time and 
temperature for ligation. Maximum yields for the ligated product were obtained when 100 µM of 
short peptide and 100 µM of CaCl2 were used at 37 °C for 5 hours (Figure 2.9).  
 Using these optimized ligation conditions and stirring the 100 µM of the LctM-modified 
core with the loaded Ni beads, the ligated peptide was observed in the solution upon MALDI-TOF 
MS analysis as shown in Figure 2.10. HPLC purification afforded the clean ligated peptide wherein  
 
 
Figure 2.9 MALDI-TOF MS spectrum of STEPL of the McbA leader with the test peptide, 
GGG (100 µM) in the presence of 100 µM CaCl2 at 37 °C. McbA leader shown contains an 
additional motif from McbA spacer region, VGIGG at the C-terminus and TwinStrep tag at the N-
terminus. m/z calculated for [M+H]+ peak for ligated product, McbA leader-LPET-GGG = 








Figure 2.10 MALDI-TOF MS spectrum of the product of STEPL of McbA leader with LctM-
modified hybrid core (100 µM) in the presence of 100 µM CaCl2 at 37 °C. In this case, McbA 
leader and the core are not separated by the additional spacer region, VGIGG (see Figure 2.8). The 
peaks observed in the absence of core peptide were due to non-specific binding of E. coli proteins 
to the column. m/z calculated for [M+H]+ peak for ligated peptide = 6479.45, m/z observed for 






2.4.3 McbBCD in vitro assay29 
 The last step in the strategy was to feed the purified hybrid peptide to the MbcBCD 
complex for the installation of thiazoles and oxazoles. McbB, McbC and McbD were purified as 
reported earlier.29 To test the activity of the ternary complex, and to test the feasibility of the in 
vitro reaction in our hands, a control experiment was performed using the wild type precursor 
peptide McbA as the substrate. After the in vitro reaction followed by thrombin cleavage to remove 
the Maltose Binding Protein (MBP) tag, MALDI-TOF MS analysis showed that the precursor 
peptide underwent nine-fold modifications each accompanied with a loss of 20 Da after 12 h 
incubation at RT (Figure 2.11). However, when the ligated peptide was incubated with the 
McbBCD enzymes (10 µM), no modifications were observed even after 24 h.  
 
 
Figure 2.11 McbBCD in vitro assay with MBP-tagged native precursor peptide, wt-McbA 
followed by thrombin cleavage. MALDI-MS analysis shows loss of 180 Da accounting for nine 
modifications introduced in the core peptide. m/z calculated for [M+H]+ peak for 9-fold modified 
peptide = 6116.12, m/z observed for [M+H]+ peak for the same = 6117. 
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2.4.4 Optimizations for the in vitro reaction with McbBCD enzymes 
 To optimize the final step, we looked closely at all possibilities that might cause 
interference with the binding and modifications by McbBCD enzymes. The first possibility was 
that the recognition motif of sortase, LPET, present in the linker region might hinder the binding 
of the peptide to the active sites of the McbBCD complex. The second possibility was that the 
LctM-installed thioether rings at the C-terminus of the peptide caused too large a perturbation from 
the linear peptide sequence for the enzyme complex to bind to the peptide and/or act on the 
modifiable residues in the core peptide.  
 To test the first possibility, a control experiment was designed wherein the LPET motif 
was introduced into wt-McbA in place of Gly residues at the same position as in the ligated peptide. 
Upon incubating this control peptide with McbBCD enzymes followed by thrombin cleavage to 
remove the MBP-tag, the peptide was observed to undergo the desired nine modifications (Figure 
2.12), which ruled out the possibility that replacement of the GGGG motif with LPET in the linker 
region of the precursor peptide was causing the observed absence of oxazole/thiazole installation 




Figure 2.12 McbBCD in vitro assay with MBP-tagged McbA mutant with LPET motif 
replacing GGGG residues from position 6 to 9, followed by thrombin cleavage. MALDI-MS 
analysis shows loss of 180 Da accounting for nine modifications introduced in the core peptide. 
m/z calculated for [M+H]+ peak for 9-fold modified peptide after thrombin cleavage= 6326.37, 





 This result, while disappointing, emphasized how important the order of installation of 
these post-translational modifications (PTMs) is for creating hybrid RiPP products with any 
combination and variety of PTMs. In order to address the problem at hand, we envisioned three 
approaches. First, introduce a spacer region between the motif derived from McbA, and the 
Ser/Thr/Cys in the LctA core peptide that can be acted upon by LctM. Since no crystal structure 
has been reported for the McbBCD complex, the length of the spacer region would have to be 
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optimized by trial-and-error. Second, to use a cyclization-impaired mutant of LctM37 which would 
only carry out dehydrations of Ser and Thr but no cyclizations. Alternatively, we could use the 
nisin biosynthetic machinery as opposed to lacticin 481 since the nisin gene cluster has two 
separate enzymes, one for dehydration (NisB) and one for cyclization (NisC) that can act 
independent of each other.10, 38 So, the NisC-installed thioether rings could be introduced after the 
McbBCD assay.  Finally, we considered changing the order in which we installed the PTMs, 
starting with thiazoles and oxazoles first since they resemble a natural amino acid Pro chemically 
and would not drastically disrupt the flexibility of the peptide. But with that strategy, we might run 
into the problem of regioselectivity by having no control over McbBCD enzymes potentially 
modifying Ser/Cys in the motif derived from LctA.  
 Despite having these future directions in mind, we realized that we needed to refine our 
strategy so as to not have to define the order of installations of PTMs by trial-and-error method (to 
be tested in the final step of the strategy) but to let the kinetic and thermodynamic parameters carve 
out the map for the formation of one or many products, as the case maybe, and then through 
optimizations, guide the pathway towards the desired species, just as nature has been doing for 
millions of years in evolving the enzymes and optimizing the structure of natural products. Charles 
Darwin said the underlying principle for all events is the survival of the fittest, how you define fit 
varies from physically/chemically endowed to energetically favorable in the grand scheme of 
events.39 The new and improved strategy is discussed in the next chapter.  
 
2.5 Methods 
All oligonucleotides, restriction endonucleases, and DNA polymerases were purchased 
from Integrated DNA Technologies, New England Biolabs or Invitrogen. Media components for 
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bacterial cultures were purchased from Difco laboratories. Chemicals were purchased from Fisher 
Scientific or from Aldrich unless noted otherwise. Non-canonical amino acids were purchased 
from Chem Impex International. Solvents commonly used in peptide purification, including 
trifluoroacetic acid (TFA) and acetonitrile,40 were obtained in RP-HPLC grade or better and used 
directly without further purification. Endoproteinase GluC and LysC were purchased from Roche 
Biosciences or Worthington Biosciences. E. coli DH5α was used as host for cloning and plasmid 
isolation, and E. coli BL21 (DE3) was used as a host for co-expression. 
 
2.5.1 General methods 
All polymerase chain reactions (PCR) were carried out on a C1000™ thermal cycler (Bio-
Rad). DNA sequencing was carried out by ACGT Inc. using appropriate primers. Matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-TOF MS) was carried out 
on a UltrafleXtreme TOF/TOF mass spectrometer (Bruker Daltonics) at the Mass Spectrometry 
Facility (UIUC). 
 
2.5.2 Construction of histagged-lctA/A-1E/GGGGSCG/N17R/lctM/pRSFDuet-1 
The mutations were introduced in four steps by the QuickChange method using Histagged-
lctA(wt)/lctM/pRSFDuet-1 as template.41 The primers are listed in Table 2.2. In the first step, A-
1E/K1G mutations were introduced followed by S4G/G5S mutations. In the third step, CG was 
inserted between S5 and V6. And, finally N17 was mutated to R. For all PCR amplifications, the 
following conditions were used: denaturation (98 °C for 20 s), annealing (appropriate temp for 45 
s), and extension (70 °C for 5 min) over 20 cycles. The PCR reaction included 25 µL of KOD 
HotStart master mix, 50-100 ng of template DNA and primers (1 µM each) in a total volume of 50 
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µL. The amplification products were run on a 1% agarose gel. The 50 µL PCR reaction mixture 
was incubated with 2 µL DpnI and 5 µL of NE Buffer 4 at 37 °C for 1 h. After incubation, the 
reaction mixture was purified using a QIAquick PCR Purification Kit (QIAGEN) and 5 µL of the 
final solution was used for transforming E. coli DH5a cells via heat shock and were plated on 
Luria Bertani (LB)-kanamycin agar plates and grown at 37 °C for 18 h. Four colonies were picked 
and incubated in 10 mL of LB-kanamycin medium at 37 °C for 14 h, followed by isolation of the 
plasmids using a QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmids 
were confirmed by DNA sequencing. 
 
2.5.3 Construction of histagged-lctA/K1insGGGGSCG/N22R/F28H/lctM/pRSFDuet-1 
The gblock Histag-EcoRI-LctA_K1G2instGGGGSCG_N22R_F28H_NotI_pRSFDuet 
shown in Table 2.2 was ordered from Integrated DNA Technologies and digested with EcoRI and 
NotI overnight. The histagged-lctA(wt)/lctM/pRSFDuet-1 was digested with the same restriction 
enzymes overnight and purified by QIAquick PCR Purification Kit. The resulting DNA inserts (50 
ng) were ligated with the respective digested vector in the ratios 1:3 and 1:10 at 50 °C for 2 h using 
10 µL of Gibson ligation master mix (NEB) in a 20 µL reaction. After incubation, 10 µL of reaction 
mixture was used for transformation of E. coli DH5a cells, and the cells were plated on LB-
kanamycin agar plates and grown at 37 °C for 18 h. Colonies were picked up and incubated in 10 
mL of LB-kanamycin medium at 37 °C for 14 h, followed by isolation of the plasmids using a 
QIAprep Spin Miniprep Kit (QIAGEN). The sequences of the resulting plasmids were confirmed 




2.5.4 Construction of McbAleader-VGIG-LPET-linker-SrtA/pRSFDuet-1 
The plasmid was prepared by digesting gblock TwinStrep_McbAld_VGIGG_LPETG 
shown in Table 2.2 and empty pRSFDuet-1 separately with NdeI and XhoI restriction enzymes 
overnight, and then ligating the digested DNA fragments through Gibson ligation as described 
above. The TwinStrep tag was removed using restriction enzymes, NdeI and NheI, and the plasmid 
was ligated back together via Gibson ligation protocol. 
 
2.5.5 Construction of MBP-McbA/GGGG6to9LPET/pET15b 
The GGGG6to9LPET mutations were introduced via QuikChange as described above 















Table 2.2 Oligonucleotide sequences of primers used for preparing plasmids. 
 
Primer Name Primer Sequence (5'-3') 
LctA/A-1E/K1G/FP GAA TTG GAC CTT ATT TTA GGT GAA GGC GGC GGC 
AGT GGA GTT ATT CAT AC 
LctA/A-1E/K1G/RP GTA TGA ATA ACT CCA CTG CCG CCG CCT TCA CCT AAA 
ATA AGG TCC AAT TC 
LctA/S4G/G5S/FP CTT ATT TTA GGT GAA GGC GGC GGC GGC AGC GTT ATT 
CAT ACA ATT TCT CAT GAA TG 
LctA/S4G/G5S/RP CAT TCA TGA GAA ATT GTA TGA ATA ACG CTG CCG CCG 
CCG CCT TCA CCT AAA ATA AG 
LctA/CGinstbeforeV6/FP CTT ATT TTA GGT GAA GGC GGC GGC GGC AGC TGC 
GGC GTT ATT CAT ACA ATT TCT CAT G 
LctA/CGinstbeforeV6/RP CAT GAG AAA TTG TAT GAA TAA CGC CGC AGC TGC CGC 
CGC CGC CTT CAC CTA AAA TAA G 
LctA/N15R/F21H/FP 
 
CAT ACA ATT TCT CAT GAA TGT CGT ATG AAT AGC TGG 
CAA CAT GTA TTT AC 
LctA/N15R/F21H/RP GTA AAT ACA TGT TGC CAG CTA TTC ATA CGA CAT TCA 














ATG GGC AGC AGC CAT CAC CAT CAT CAC 
CAC AGC CAG GAT CCG AAT TCG ATG AAA 
GAA CAG AAC TCC TTC AAC CTG CTG CAG 
GAA GTG ACC GAA AGC GAA CTG GAT CTG 
ATT CTG GGT GCA AAG GGC GGT GGC GGT 
TCT TGT GGC GGC GGC AGC GGC GTA ATC 
CAC ACC ATC AGC CAC GAG TGT CGT ATG 
AAC TCT TGG CAG CAT GTA TTC ACC TGC 
TGC AGC TAA GCG GCC GCA TAA TGC TTA 
AGT CGA ACA GAA AGT AAT CGT ATT GTA 
CAC GGC 
SrtAend/HisTag/XhoI/RP AAT AAT CTC GAG TTA ATG ATG ATG ATG ATG 
ATG TTT GAC TTC TGT AGC TAC AAA GAT TTT 
ACG TTT TTC 
NdeI/(GGS)5/SrtA-59/FP ATT ATT CAT ATG GGC GGC AGC GGC GGC 
AGC GGC GGC AGC GGC GGC AGC GGC GGC 
AGC CAA GCT AAA CCT CAA ATT CCG AAA 
GAT AAA TC 
TwinStrep_McbAld_VGIGG_LPETG 
 
GAT AAC AAT TCC CCA TCT TAG TAT ATT AGT 
TAA GTA TAA GAA GGA GAT ATA CAT ATG TCA 
GCT TGG TCA CAC CCA CAA TTC GAA AAG 
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Table 2.2 (cont.)  
 
 GGT GGT GGA TCA GGA GGA GGT TCA GGA 
GGT TCT GCA TGG TCA CAT CCA CAG 
TTCGAGAAGGCTAGC ATGGAACTGAAAG 
CTTCCGAATT CGGTGTGGTA CTGAGCGTTG 
ACGCTCTGAA GCTGAGCCGC CAGTCTCCTC 
TGGGT GTG GGC ATT GGC GGT CTGCC 
GGAAACCGGC GGC GGC AGC GGC GGC AGC 
GGC GGC AGC GGC GGC AGC GGC GGC AGC 
CAAGCTAAACCTCAAATTCCG 
McbA_6LPET9_newFqc          
    
CA TTA GGT GTT GGC ATT GGT GGT CTG 
CCG GAA ACC GGC GGC GGC GGT AG 
McbA_6LPET9_Rqc CTA CCG CCG CCG CCG GTT TCC GGC AGA 











Table 2.3 List of plasmids used. 
Plasmid Marker Insert/Mutation Reference 
histagged-lctA(wt)/ 
lctM/pRSFDuet-1 
Kanamycin Histagged-lctA(wt) inserted 
between EcoRI and NotI 
sites; lctM inserted between 







inserted before V6 in wt-







Kanamycin GGGGSCG inserted between 
K1 and G2 of lctA(wt); N22R 





Chloramphenicol lctM gene inserted between 




Spectinomycin lctM gene inserted between 












srtA gene from 
Staphylococcus aureus (strain 
N315) with 1-59 residues 
deleted, GB1 tag on N 










inserted as gblock, TwinStrep 
tag removed later 
This 
work 




Ampicillin GGGG(6 to 9) mutated to 
LPET using MBP-
McbA/pET15b as template 
This 
work 
MBP-McbB/pET15b Ampicillin MBP-tagged mcbB gene 29 
MBP-McbC/pET15b Ampicillin MBP-tagged mcbC gene 29 







2.5.6 Protein expression and purification 
E. coli BL21(DE3) cells were transformed with plasmids encoding the tagged proteins and 
selected using appropriate antibiotics. Starter cultures were grown in 10 mL of LB with antibiotics 
and used to inoculate 1 L of similarly prepared media. After reaching an OD600 of ~0.8, cells were 
induced with IPTG. For the sortase-fused proteins, the overexpression was carried out at 37 °C for 
4 h with 1 M IPTG, and the other overexpressions were performed at 18 °C with 250-400 mM 
IPTG for 16-20 h. 
Next, cells were harvested by centrifugation at 4000 ´ g for 30 min at 4 °C. Cell pellets 
were stored at –20 °C. Proteins used for in vitro assays were purified using affinity 
chromatography via the MBP tag. MBP-tagged proteins were purified from E. coli cells using 
amylose resin (NEB). The resin was pre-equilibrated with 5 bed volumes of Buffer A [50 mM Tris 
pH 7.5, 500 mM NaCl, 2.5% (v/v) glycerol, 0.1% (v/v) Triton X-100]. Cell pellets were suspended 
in Buffer A and sonicated three times for 30 s at 10-13 W using a Misonix MICROSON XL2000 
Cell Disruptor with 10 min incubations at 4 °C between each 30 s sonication period to prevent 
sample heating. The lysate was clarified by centrifugation at 34000 ´ g for 1 h, and applied to the 
equilibrated resin, and washed with 10 bed volumes of Buffer B [50 mM Tris pH 7.5, 400 mM 
NaCl, 2.5% (v/v) glycerol]. Protein was then eluted using Elution Buffer [50 mM Tris pH 7.5, 300 
mM NaCl, 2.5% (v/v) glycerol, 10 mM maltose] and collected into Amicon Ultra 15 mL Filter 
centrifugal filters [30kDa NMWL (Nominal Molecular Weight Limit)]. The eluted protein was 
concentrated and a buffer exchange was performed into Storage Buffer thrice [50 mM HEPES, 
300 mM NaCl, 2.5% (v/v) glycerol] through centrifugation at 4000 ´ g. The final protein 
concentration was calculated from the absorbance at 280 nm (NanoDrop 2000 UV-Vis 
Spectrophotometer) with the predicted protein extinction coefficient 
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(http://web.expasy.org/protparam/). All proteins were stored at –80 °C. Note that after initial 
column loading, all wash and storage buffers were supplemented with 1 mM tris-(2-
carboxylethyl)-phosphine (TCEP). 
 
2.5.7 Purification of MBP-tagged or His-tagged peptides 
All peptides that were MBP-tagged were purified as described above. Typically, >20 mg 
of MBP-tagged peptide (corresponding to >1 mg of substrate after affinity tag removal) was 
obtained from 1 L of culture. 
The His6-tagged peptides were purified by the following procedure. The harvested cells 
were resuspended in 25 mL of LanA Buffer 1 [6 M guanidine hydrochloride, 20 mM NaH2PO4, 
pH 7.5 at 25 °C, 500 mM NaCl, 0.5 mM imidazole], and lysed by sonication (50% amplitude, 1.0 
s pulse, 2.0 s pause, 5 min). The sample was subjected to centrifugation (23,700 × g for 30 min at 
4 °C) and the supernatant containing the His6-tagged peptide was retained for further purification. 
The His6-tagged peptide was then purified by immobilized metal affinity chromatography (IMAC) 
using 2-4 mL of His60 Ni Superflow Resin (Clontech). The supernatant was applied to the column 
and the column was washed with two column volumes of LanA Buffer 1 followed by two column 
volumes of LanA Buffer 2 [4 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 300 
mM NaCl, 30 mM imidazole], and then eluted with three column volumes of LanA Elution Buffer 
[4 M guanidine hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 mM NaCl, 1 M imidazole]. The 
elution fractions containing the peptide were desalted by using a Vydac C4 SPE column and 




2.5.8 Proteolysis of full-length His-tagged peptides, and HPLC purification  
After solid phase extraction, the full-length peptides were purified further on a C5-
Phenomenex column using a Shimadzu Prep-HPLC Instrument and were observed to elute in a 
time range of 22-24 min when the gradient was set from 2% solvent B to 100%A (solvent A = 
0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) over a time period of 
45.0 min at a flow rate of 7.0 mL /min. The full-length hybrid peptides were proteolytically cleaved 
by LysC or GluC at a concentration of 1:100 (w/w) in 50 mM Tris buffer (pH 8.0) overnight at 
room temperature. The extent of cleavage was monitored using MALDI-TOF MS. The peptides 
were then purified using a C18-Phenomenex column on an Agilent Analytical HPLC Instrument 
and were observed to elute in a time range of 21-23 min when the gradient was set from 2% solvent 
B to 100%A (solvent A = 0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) 
over a time period of 45.0 min at a flow rate of 1.0 mL /min. 
 
2.5.9 STEPL ligation33  
A 500 mL culture of cells expressing McbAleader-VGIGG-LPET-linker-SrtA/del1-
59/pRSFDuet-1 were harvested by centrifugation and resuspended in 10 mL of lysis buffer (50 
mM NaH2PO4, 300 mM NaCl, 1 mg/mL lysozyme, 1 EDTA-free Complete Mini protease inhibitor 
tablet (Roche), pH 7.5). Lysates were incubated at room temperature for 30 min while gently 
shaking, and then sonicated for 4 min and then centrifuged at 7000 x g for 15 min. The supernatant 
was then incubated with 0.3 mL of His60 Ni Superflow Resin (Clontech, pre-equilibrated with 
lysis buffer) for an hour.  Then, the resin was added to a column and washed with 10 mL of STEPL 
buffer (20 mM Tris-base, 50 mM NaCl, pH 7.5). The beads were resuspended in 1.5 mL of STEPL 
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buffer with 100 µM of CaCl2 and the ligating partner, and incubated at 37 °C while gentle rocking. 
The progress of the reaction was monitored by MALDI-TOF. 
 
2.5.10 McbBCD in vitro assay29 
The MBP-tagged McbB, McbC and McbD proteins were pooled at a 1:1:1 molar ratio such 
that the overall concentration of each was 100 µM. To this sample, 0.2 µg of thrombin (from bovine 
plasma) was added, and the sample was proteolytically digested for 4 h at 22 °C to remove the 
MBP tags. A 300-µL sample of 20 µM MBP-McbA and low-salt synthetase buffer (50 mM Tris 
pH 8.5, 25 mM NaCl, 5 mM MgCl2, 10 mM dithiothreitol, 5 mM ATP, pH 8.0) and the above 
mixture of McbB, McbC and McbD was added to a final concentration of 10 µM to initiate the 
reaction. The reaction was monitored after 5-, 10- and 24 h time periods via MALDI-TOF MS 
after thrombin cleavage. 
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Chapter 3: Leader-Peptide Guided Generation of Non-Natural Hybrid RiPP Products – 




Bryce Dallas Howard said in Jurassic World “our advances in gene splicing have opened 
up a whole new frontier. We have learned more from genetics in the past decade than a century of 
digging up bones’’. Indeed, genetic advancements have uncovered an ability to glimpse at our 
evolutionary timeline: what events might have happened in the past, how we arrived at our present 
state of being, and what we can potentially achieve in the future.1-6 Of course, humankind would 
like to understand and achieve all three, but most important may be the last category. Genome 
sequencing projects can help us in advancing synthetic biology to not just engineer analogues of 
natural products that we have come to know as highly potent drugs, but to also create new 
molecules that have never been produced/isolated under natural stimuli from their host strains.4-6 
As mentioned in the previous chapter, one approach to accessing new structural and functional 
space is through bioengineering of new-to-nature hybrid molecules that may have desired chemical 
and biological properties and applications in the pharmaceutical and food industry. 
Looking at the evolution of biosynthetic pathways in nature, several factors play a role in 
determining the product: enzymes kinetics, substrate specificity and enzyme promiscuity, 
environmental stresses and the subsequent changes in the desired concentration and functional role 
of the natural product, the metabolic rate of production, and positive or negative feedback loops 
resulting in rate enhancement or inhibition, respectively.7, 8 Therefore, designing a biosynthetic 
                                                        
* Reproduced in part with permission from Burkhart, B.J.; Kakkar, N.; Hudson, G.A.; van der Donk, W.A.; 
Mitchell, D.A. Chimeric leader peptides for the generation of non-natural hybrid RiPP products. ACS Cent. Sci. 
2017, 6, 629-638. Copyright 2017 American Chemical Society. Dr. Brandon Burkhart contributed towards section 
3.2.2 and 3.3. 
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route to create a new molecule needs an iterative process with high turnaround so that different 
permutations and combinations of biosynthetic enzymes can be tested: their number, their 
compatibility, and their order of action in the scheme. Since our attempts described in chapter 2 
using the ‘swapping leader peptides’ approach was not very high-throughput, we needed a new 
approach for combinatorial biosynthesis. 
A different way to understand the recognition of precursor peptides and their subsequent 
modification by RiPP biosynthetic enzymes is by identifying the conserved recognition residues 
in the leader peptide (called recognition sequences, RS) and enzymes (called RiPP recognition 
element, RRE), either found together as a motif in their 1D structure or brought together spatially 
through coevolution of amino acids to adopt a specific conformation in the 3D structure for/upon 
binding to the enzyme.9-16 Recently, it was reported that the majority of known prokaryotic RiPP 
enzymes contain a conserved ∼90-residue PqqD-like domain as RRE, which allows them to bind 
to the RSs in the leader peptides in most reported cases.15 Since the leader peptide-binding domain 
and the catalytic domain of RiPP modification enzymes are spatially apart, they are able to perform 
with high specificity (at the leader peptide-binding site) as well as high promiscuity (at the catalytic 
site).15, 17 
Taking advantage of the RSs on the leader peptides and the corresponding RREs on 
modification enzymes (not considering exceptions wherein the leader peptide-dependent enzymes 
lack this domain or do not use it),18-20 we envisioned a “chimeric leader peptide” strategy that 
would enable the rational combination of RiPP modifications. In this method, RSs from two leader 
peptides are concatenated to form a new bifunctional leader peptide within a single precursor 
peptide. With their native RSs present, we hypothesized that two primary modifying enzymes 
would bind to the respective regions on the chimeric leader peptide and sequentially install 
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posttranslational modifications, resulting in a hybrid RiPP product. In the following sections, it 
will be demonstrated that, after optimizing the core sequence and properly designing the 
coexpression plasmids, this approach successfully combines a thiazoline forming 




Figure 3.1 Overview of RiPP biosynthesis.† (a) A generic RiPP gene cluster and the key 
maturation steps. (b) Chimeric leader peptide strategy for combining modifying enzymes from 
unrelated pathways. Examples of primary RiPP modification enzymes combined in this work 
include (c) azoline-containing RiPPs, and (d) Cβ-cross-linked lanthipeptides. (e) Examples of 
secondary RiPP modification enzymes used in this work to install D-Ala residues and 
decarboxylate C-terminal Cys residues. 
                                                        
† Edited version of figure made by Dr. Brandon Burkhart from the Mitchell laboratory at UIUC. 
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including class I and II lanthipeptides (NisB/C and ProcM, respectively; Figure 3.1c and 3.1d). 
We also demonstrate how leader peptide-independent tailoring enzymes such as NpnJA and MibD 
(Figure 3.1e) can be included. Therefore, this chapter details a broad foundation for the generation 




3.2.1 Thiazoline-lanthipeptide (class I) hybrid 
In order to test our underlying hypothesis of chimeric leader peptides being able to direct 
different RiPP biosynthetic enzymes to act on the same core peptide, we first sought to combine 
an azoline forming cyclodehydratase (HcaD/F) with a lanthipeptide synthetase (NisB/C). HcaD/F 
is a thiazoline-forming cyclodehydratase (Figure 3.1d) and was chosen because of two main 
reasons: 1) the RS of the precursor peptide (HcaA) was identified to be towards the N-terminus of 
the leader (Figure 3.2a ), and 2) because of the long HcaA leader, we had an opportunity to replace 
the second half that is not important for enzyme binding to make a hybrid leader.21, 22 NisB 
(dehydratase) and NisC (cyclase) are involved in biosynthesis of the class I lantibiotic nisin. In a 
first-of-its-kind mechanism, NisB/C forms the characteristic lanthionine (Lan) or 
methyllanthonine (MeLan) rings found in lanthipeptides through a two-step process involving 
glutamyl-tRNA.17, 23 First, NisB catalyzes dehydration of Ser/Thr residues to form the 
corresponding dehydroalanine (Dha) or dehydrobutyrine (Dhb) in a tRNA-dependent manner.17, 23 
Next, NisC catalyzes a 1,4-nucleophilic addition of a Cys thiol to the Cβ of the dehydro-amino 
acid to form a thioether ring.24 The vast number of reports investigating how and where NisB/C 
bind to and modify the precursor peptide NisA and its mutants made it an ideal candidate to be 
used in this strategy (Table 3.1).25-28  
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Table 3.1 Sequence and position dependence of dehydration by NisB. A concise summary of 
findings about the extent of dehydration of different NisA mutants by NisB. The notation 
XXXX(−ato−b)YYYY implies XXXX motif from position −a to −b in the peptide was replaced 
by YYYY motif. The entries shown in red are for the positions in the C-terminal region of the 
NisA leader which were being investigated in this study.25-28  
 
NisA 
                −20                              −10                             −1 
MSTKDFNLDLVSVSKKDSGASPR – ITSISLLCTPGCKTGALMGCNMKTATCHCSIHVSK 
 
   




Role played in nisin biosynthesis 
STKD(−22to−19)AAAA Complete Important for binding to NisB and forming 
complex with NisT, but not for dehydrations 
FNLD(−18to−15)AAAA Up to 4 Important for interactions with NisB and 
NisC, and for dehydrations 
VSVSKK(−13to−8)HHHHHH 8 The residues towards the N-terminus of 
NisA leader are more important for binding 
to NisB and their substitution to Ala reduces 
the number of dehydrations 
LVSV(−14to−11)AAAA Up to 3 
SKKD(−10to−7)AAAA Up to 4 
SGAS(−6to−3)AAAA Between 4-8 
GASPR(−5to−1)DDDDK 8 Yields go down 
ASP(−4to−2)VSL 8  
ASP(−4to−2)IDG 8  
ASP(−4to−2)IEG 8  
ASPR(−4to−1)DDDK 8  




A chimeric precursor peptide was constructed from the HcaA and NisA precursor peptides 
to serve as a potential substrate for both HcaD/F and NisB/C (Figure 3.1a). To incorporate both 
the RS from HcaA and NisA, we replaced the non-essential C-terminal region of the HcaA leader 
peptide with the essential region of the NisA leader peptide.22 We next engineered the core region 
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of the chimeric precursor peptide. Since the C-terminus of the NisA leader peptide is amenable to 
substitutions without significant impairing catalysis (see Table 3.1), we inserted a “GGRCG” motif 
derived from the HcaA core peptide in the C-terminal region of the NisA leader as shown in Figure 
3.2a at a position that would be appropriately distanced from the RS of HcaA to facilitate HcaD/F 
processing but too close to the NisA RS to allow for NisB/C processing. This motif was then 
followed by the native NisA core sequence so that it would be spaced approximately at a similar 
distance from the NisA RS on the chimeric leader peptide as it is in NisA itself. Through this 
example, we set ourselves to test three main challenges: 1) whether the presence of two potentially 
competing RREs would cause interference in creating a hybrid 2) whether a chimeric leader 
peptide (LP) can be designed when both the RREs are near the N-terminus of their respective LPs, 
−8 to −4 of HcaA LP, and −18 to −15 of NisA LP, which makes it more challenging for the design 
of a chimeric leader peptide, and 3) whether we can combine four RiPP primary modification 
enzymes, namely NisB, NisC, HcaD and HcaF. 
The designed hybrid peptide, named Hyp 1.1, was tested by expressing HcaD/F, NisB/C, 
and His6-Hyp1.1 in Escherichia coli (see Table 3.3 for plasmids). Co-expressions of the peptide 
with HcaD/F or NisB/C separately acted as controls. The modified peptide was affinity purified, 
and analyzed via MALDI-TOF mass spectrometry (Figure 3.2b). As can be seen from Figure 3.2c, 
only when all four enzymes were expressed, did the peptide undergo close to the maximum extent 
of modifications (the maximum being ten dehydrations). We do not at present know why co-
expression of all four enzymes with the hybrid peptide leads to much better conversion than when 
the peptide is co-expressed with only two enzymes. One possible explanation is that co-expression 
of all four proteins and the His6-tagged peptide results in less precursor peptide because of the 
additional protein expression burden and therefore the peptide that is produced is more completely  
 73 
 
Figure 3.2 Production of a thiazoline−lanthipeptide (class I) hybrid Hyp1.1. (a) Design of the 
Hyp1.1 sequence from HcaA and NisA precursor peptides. The portions of the leader peptides that 
were combined are colored. The recognition sequences (RSs) bound by the RREs of the cognate 
enzymes are indicated with a pink box. The orange underlined regions were combined to generate 
the chimeric core region. (b) Overview of experimental procedure. Numbering is based on the core 
position, not peptide length after digestion. (c) The peptide was most modified when co-expressed 
with HcaD/F and NisB/C, and had up to nine losses of water molecules as analyzed via MALDI 
TOF-MS. m/z calculated for [M+H]+ peak for 9-fold dehydrated peptide = 10659, m/z observed 





modified. Since both NisB-catalyzed dehydrations and HcaD/F-catalyzed cyclodehydrations 
involve a 18 Da change, analysis of the products was challenging. Thus, we needed a way to reduce 
the number the products we observed and then carefully ascertain the type of modifications that 
were associated with a given product. Therefore, we decided to truncate the NisA part of the core 
peptide from the C-terminus at Met 24 (Figure 3.3a). We assumed that would not be a problem as 
long as NisB/C would still modify residues from the N-terminus to the C-terminus of NisA as 
observed for the wild type system.29  
Upon co-expression with HcaD/F and NisB/C, the hybrid peptide Hyp1.2 was affinity 
purified and digested with AspN and analyzed by MALDI-TOF MS (Figure 3.3b). A mixture of 
products was observed with the most modified species having lost six water molecules (Hyp1.2a 
in Figure 3.3c), one more than what we expected from dehydration of the NisA core segment, 
which implied that one Cys residue was cyclodehydrated. To probe the structure of the most 
processed species, we leveraged the fact that thiazolines are readily hydrolyzed to Cys under mild 
acid treatment with a concomitant gain of 18 Da and we did indeed observe a gain of 18 Da upon 
mild acid treatment (Figure 3.3c). Treatment with iodoacetamide under reducing conditions, which 
would alkylate free Cys, yielded very little product suggesting that the thioether rings were formed 





Figure 3.3 Production of a thiazoline−lanthipeptide (class I) hybrid peptide. (a) Design of the 
Hyp1.2 sequence from HcaA and NisA precursor peptides. Portions of the leader peptides that 
were combined are colored. The sequences of Hyp1.1 and Hyp1.2 peptides are shown to highlight 
the optimizations made. (b) Overview of experimental procedure. (c) The mass of Hyp1.2a 
(MALDI-TOF-MS) is consistent with one thiazoline, three dehydrations, and two (Me)Lan. These 
modifications are supported by acid hydrolysis (blue arrow, +18 Da) and by lack of significant 
labeling by iodoacetamide (green arrow, +57 Da). m/z calculated for [M+H]+ peak for 6-fold 





Since the most processed species was not the major product, we further truncated the NisA 
core region to Thr20 and mutated Thr20 to Ala. Our hypothesis was that Thr20, being towards the 
C-terminus, was the last residue to be dehydrated by NisB,29 and was poorly modified (Figure 
3.3a). Upon co-expression of the new hybrid peptide, Hyp1.3, with four enzymes, followed by 
IMAC purification and AspN digestion, we again observed a mixture of products but this time the 
most extensively processed peptide, dubbed Hyp1.3a, was 5-fold dehydrated (Figure 3.4d). If fully 
modified, it would contain one thiazoline, one Dhb, one Dha, one MeLan, and one Lan (Figure 
3.4c and 3.4d). To confirm the structure, we performed mild acid hydrolysis, which resulted in a 
concomitant gain of 18 Da and no significant adduct formation upon treatment with iodoacetamide 
under reducing conditions, consistent with the proposed structure. 
While previous nisin biosynthetic manipulation introduced new tailoring enzymes from 
related pathways30, 31 and hybrids have been synthetically prepared,32, 33 the enzymatic 
incorporation of a non-native modification (thiazoline) has not been reported. Our data show the 
feasibility of combining disparate RiPP pathways to generate new-to-nature hybrids by rationally 
designing a chimeric leader peptide. These results also demonstrate that two RiPP enzymes that 
compete for modification of the same residue (Cys) can still be rendered compatible. In this first 
example, discrete regions in Hyp1.3 were used to mimic the native peptides and a similar approach 




Figure 3.4 Production of a thiazoline−lanthipeptide (class I) hybrid. (a) Design of the Hyp1.3 
sequence from HcaA and NisA precursor peptides. Portions of the leader peptides that were 
combined are colored. (b) Overview of experimental procedure. (c) Structure of 
thiazoline−lanthipeptide (class I) hybrid Hyp1.3a upon AspN digestion. Thiazolines are blue while 
dehydrations and (Me)Lan are red. Numbering is based on the core position, not peptide length 
after digestion. (d) The mass of Hyp1.3a (MALDI-TOF-MS) is consistent with one thiazoline, two 
dehydrations, and two (Me)Lan. These modifications are supported by acid hydrolysis (blue arrow, 
+18 Da) and by lack of labeling by iodoacetamide (green arrow, +57 Da). m/z calculated for 
[M+H]+ peak for 5-fold dehydrated peptide = 3234.76, m/z observed for [M+H]+ peak for the 5-
fold dehydrated peptide = 3233. 
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3.2.2 Hybrids made with a secondary tailoring enzyme, the reductase NpnJA 
In addition to showcasing the use of chimeric leader peptides for primary biosynthetic 
enzymes, we investigated its utility for general use since some natural biosynthetic gene clusters 
incorporate secondary tailoring enzymes that install functional groups critical for bioactivity of the 
finished products.34 We chose to investigate a combination of the same cyclodehydratase, HcaD/F 
and the class II lanthipeptide synthetase ProcM, a highly promiscuous enzyme that acts on 30 
different native precursor peptides (ProcAs) and installs rings of different size and topology.35-38 
Therefore, we envisioned it would make a good candidate to explore other designs of the hybrid 
core peptides. Furthermore, with ProcM the diversity of examples would be expanded to include 
a case wherein the leader peptide does not have a RRE.18  
Regarding the design of the chimeric leader peptide, since only the C-terminal residues of 
ProcA leader are essential for binding to ProcM and the majority of the N-terminus is 
dispensable,35 our collaborators, Professor Douglas A. Mitchell and Dr. Brandon Burkhart, 
introduced the last nineteen residues of the ProcA3.3 leader peptide after the first 25 residues of 
the HcaA leader region. For the core region, the entire core peptide of Proc3.3 with a Thr18Ala 
mutation was used so as to prevent Cys14 from forming the native MeLan ring with Thr18, and a 
Met20Asp mutation was introduced to discourage HcaD/F from cyclodehydrating Cys21. With 
this design, they showed the formation of Hyp2.1a peptide with a thiazoline moiety present within 






Figure 3.5 Deduced structure of Hyp2.1a containing a thiazoline within a MeLan.  
 
To include a tailoring enzyme for this hybrid system based on ProcA3.3 and HcaA, we 
chose the D-Ala-forming Dha reductase NpnJA from Nostoc punctiforme PCC 73102 since the 
presence of D-amino acids in a RiPP natural product can improve the proteolytic stability of 
peptides in vivo, and can help in stabilizing beneficial turns in peptides/proteins.39-43 NpnJA reduces 
Dha to D-Ala using NAPDH as co-substrate.39 While being highly substrate tolerant, NpnJA has 
been shown to prefer hydrophobic flanking residues (Leu, Val, Ile, Lys, Arg, Phe, Ala, Trp, Asn, 
and His),39 and therefore a D2V/T3S double substitution was introduced into the core peptide to 
create Hyp2.2 (Figure 3.6a). 
 Upon co-expressing Hyp2.2, HcaD/F, ProcM and NpnJA in E. coli, a minor +2 Da product 
was observed while the majority of the peptides still retained the Dha residue at position 3 in the 
core peptide. However, when we carried out the in vitro NpnJA assay39 on Hyp2.2a with NADPH 
as co-substrate overnight, we observed that the major species gained 2 Da (labeled Hyp2.2b), 





Figure 3.6 Combination of two primary and one secondary RiPP modifications. (a) Design of 
hybrid peptide. Orange underlining highlights changed residues. The dashed line indicates the 
leader peptide of the Proc3.3. (b) Experimental overview for combining HcaF/D, ProcM, and 
NpnJA. (c) Deduced structure of Hyp2.2b. (d) MALDI-TOF-MS analysis of Hyp2.2 products. The 
initially formed hybrid has a Dha, thiazoline (arrow indicates hydrolysis), and MeLan. The 
formation of D-Ala from Dha is indicated by the +2 Da shift (triangle) of the Hyp4.4a species upon 
addition of NpnJA. The weak ion labeled as M – 4H2O is likely a peptide that underwent two 
cyclodehydrations and two dehydrations. m/z calculated for [M+H]+ peak for 3-fold dehydrated 







3.2.3 Further exploration of thiazoline-lanthipeptide (class II) hybrids 
 The general tolerability of HcaD/F and ProcM with ProcA3.3 derived core sequences 
encouraged us to design a new hybrid sequence based on a peptide with a completely different 
core sequence, ProcA1.1 so that we could form MeLan rings of different ring size and topology. 
Like Hyp2.2, this hybrid (Hyp3.1) appended the HcaA minimal leader sequence to the C-terminal 
portion of the ProcA1.1 leader peptide (Figure 3.7a). To make Cys3 a better substrate for the 
cyclodehydratase HcaD/F (Cys16 was not expected to be acted on by HcaD/F as it cannot modify 
terminal Cys residues), we modified the sequence context around it to mimic the repeat sequence 
from the HcaA core peptide, “RCG” as was done in case of Hyp1.1. Additionally, we mutated, 
Thr12 to Ser since Cys thiols react faster with Dha than with Dhb residues.44 Co-expression of 
Hyp3.1 with ProcM and HcaD/F resulted in mainly unmodified peptide as the major product, and 
two partially modified minor products: a one-fold dehydrated species containing one MeLan 
between Ser12 and Cys16 and no thiazoline, and a two-fold dehydrated species containing two 
MeLan rings, exactly what we observe in prochlorosin 1.1 (Figure 3.8). So, under these conditions, 
Cys3 was either not modified at all or was forming a MeLan ring with a dehydrated Thr7. 
Therefore, to eliminate the possibility of Cys3 forming a thioether ring, Thr7 was mutated to Ala 
in Hyp3.2. Unfortunately, co-expression of MBP-tagged Hyp3.2, ProcM, and HcaD/F resulted in 
mostly unmodified peptide and a minor species with one dehydration (Figure 3.7c). Hence, 





Figure 3.7 Production of hybrid thiazoline−lanthionine (class II) hybrid, Hyp3.2. (a) Design 
of hybrid peptides. Orange underlining indicates edited positions of the core peptide. The dashed 
line indicates the leader peptide of the ProcA1.1. (b) Experimental overview for combination of 
HcaD/F and ProcM. (c) MALDI-TOF-MS analysis of Hyp3.2 products. Numbering is based on 
the core position, not peptide length after GluC digestion. m/z calculated for [M+H]+ peak for 






Figure 3.8 Structure of prochlorosin1.1 observed after ProcM installs modifications on its 
precursor peptide, ProcA1.1. 
 
 
3.2.4 Hybrids with the oxidative decarboxylase MibD as secondary tailoring enzyme 
We also successfully combined HcaD/F with MibD, a flavin-dependent enzyme from 
Microbispora sp. 107891 involved in the biosynthesis of the lanthipeptide microbisporicin, to 
produce a C-terminally decarboxylated, linear azoline-containing peptide (Figure 3.9). MibD is a 
LanD enzyme that carries out oxidative decarboxylation of a C-terminal Cys to the corresponding 
aminoenethiolate, and its preferred sequence for activity is S-(F/W/N)-(N/C)-S-(F/Y/W/N)-C-C.45 
This motif was mimicked by changing the C-terminus of the peptide Hyp4.1, derived from Proc2.8 
instead of Proc1.1 as discussed in the previous section, to SAFAC to create test peptide Hyp4.2 























Figure 3.9 Design and production of decarboxylated linear azol(in)e-containing peptide, 
Hyp4.2. (a) A hybrid peptide was designed that would enable modification by HcaD/F and the 
leader-independent tailoring enzyme MibD from Microbispora sp. 107891. Although part of the 
ProcM leader region was present, ProcM was not used in this experiment. (b) Anticipated hybrid 
biosynthesis. As both thiazoline and decarboxylation are smaller modifications occurring on 
different ends of the core peptide, the enzymes can presumably act in any order. (c) Overview of 
experiment. Hyp4.2 was co-expressed with HcaD/F in pET-3.4-FD and MibD in pCDFDuet (see 
plasmid list in Table 3.3). The peptide was purified, digested with AspN, and analyzed by MALDI 
TOF-MS. (d) The mass spectrum shows several ions, but the most intense peak (labeled Hyp4.2a) 
corresponded to the desired hybrid product. (e) Deduced structure of the hybrid Hyp4.2a product 
after AspN digestion. m/z calculated for [M+H]+ peak for Hyp4.2a = 2725.16, m/z observed for 




Figure 3.10 Chemical structure of post-translation modification, AviCys. Flavin-dependent 
LanD enzymes first oxidizes the terminal Cys to a thioaldehyde, followed by spontaneous 
decarboxylation to form the thioenolate. Attack of this enethiol onto the Dha/Dhb residue,  
yields the AviCys product.45-48 
 
The peptide was used to attempt the production of a hybrid peptide containing an AviCys 
ring as found in microbisporicin.45 Chemically, AviCys (S-[(Z)-2-aminovinyl]-D-cysteine) is 
formed by the attack of the aminoenethiolate onto a nearby Dha or Dhb (Figure 3.10).45-48 
Therefore, to provide a dehydrated residue, we added ProcM to our system. In addition to adding 
another kind of functionality to our growing repertoire of PTMs for hybrid RiPP natural products, 
this setup would also have allowed to further probe the mechanism of formation of AviCys. Till 
date, it is not known whether these rings are formed enzymatically or non-enzymatically, and 
whether its formation occurs with the help of an enzyme. In other words, it is not known whether 
the decarboxylase (LanD), the cyclase (LanC or LanM), or an unknown enzyme is involved.45-48 
Co-expression of MBP-tagged Hyp4.2 with ProcM, HcaD/F and MibD resulted in a major 
species that underwent a loss of 82 Da, a combination of 46 Da due to MibD-catalyzed oxidative 
decarboxylation and 36 Da due to the loss of two water molecules (Figure 3.11b). However, acid 
hydrolysis of the product showed the absence of a thiazoline ring, which was essential for the 
peptide to be considered a hybrid species. The lack of significant changes in the mass spectra upon 
IAA treatment under reducing conditions hints towards the formation of an AviCys ring at the C-
terminus of the peptide, however because at present it is not known if an aminoenethiolate reacts 
with IAA, this conclusion needs further verification in future work.  
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Figure 3.11 Combination of two primary and one secondary RiPP modification. (a) Overview 
of experiment. Hyp4.2 was co-expressed with HcaD/F in pET-3.4-FD, MibD in pCDFDuet and 
ProcM in pETDuet (see plasmid list in Table 3.3). The peptide was purified, digested with AspN, 
and analyzed by MALDI TOF-MS. (b) The mass spectrum shows several ions, but the most 
modified species on the left was acted upon by ProcM and MibD only as seen by lack of addition 
of 18 Da upon mild acid hydrolysis. m/z calculated for [M+H]+ peak for peptide labeled M - 36 -







Rational design of biosynthetic pathways to produce custom molecules has long been a 
goal of combinatorial biosynthesis and natural product synthetic biology. Despite progress in 
understanding natural pathways, the chemical space that can be explored by current engineering 
techniques is limited compared to what is theoretically possible.49, 50 In this work, we have 
demonstrated how a chimeric leader peptide has the potential to unlock the vast chemical space 
afforded by RiPPs. This concept was inspired by how natural pathways can combine different 
enzymes (Figure 3.11) and represents a major step forward in RiPP engineering. Although prior 
work has demonstrated enzyme swapping within related pathways, such as for nisin and the 
cyanobactins,30, 31, 51-55 this study is to our knowledge the first demonstration of leveraging the 
recognition sequences and programmability of RiPP enzymes to mix-and-match the primary, 
class-defining structural features from unrelated classes. In total, four mechanistically unique 
enzymes were shown to be tolerant to manipulation of their leader peptides and insertion of non-
native sequences. The primary difficulty we encountered was ensuring that the enzymes acted at 
the desired locations and in the correct order. Being from unrelated pathways, there were no natural 
biosynthetic checkpoints to guide processing toward a single hybrid product, meaning the enzymes 
could compete for the same residue or act in a fashion that blocked the other enzyme. However, 
modest editing of the core sequence was sufficient to exploit the innate selectivity of an enzyme 
to yield the desired product. Future work with other enzymes that exhibit different substrate 
preferences may lead to a toolbox of enzymes for use in specific applications. Optimizing 
expression levels of each enzyme through plasmid design also adds another layer of control. 
Despite the successful use of these design principles in this work, there are likely some RiPP 
modifications that are inherently incompatible or too difficult to generally combine given their  
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Figure 3.12 Natural “hybrid” RiPP biosynthetic gene clusters.‡ (a) Linear azol(in)e-containing 
peptides such as plantazolicin have only the cyclodehydratase as its primary, class-defining 
modifying enzyme. A tailoring enzyme also dimethylates the N-terminus upon leader peptide 
proteolysis. (b) Cyanobactins are defined by the presence of a PatG-like protease which recognizes 
a C-terminal motif to cyclize peptides after removal of the N-terminal leader region (by a PatA-
like N-terminal protease). However, most cyanobactin gene clusters have acquired a 
cyclodehydratase and thus install two primary modifications (azolines and N-to-C 
macrocyclization). (c) Thiopeptides have three major modifications: azol(in)es, dehydrated amino 
acids, and a 6-membered nitrogen-containing heterocycle. Because the cyclodehydratase and 
dehydratase can be found in other RiPP subclasses, the cycloaddition enzyme is the class-defining 
feature of thiopeptides. Unexpectedly the dehydratase, which is normally leader-peptide dependent 
                                                        
‡ Figure was made by Dr. Brandon Burkhart from the Mitchell laboratory at UIUC. 
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Figure 3.12 (cont.) in lanthipeptide pathways,56 acts in a leader independent fashion in 
characterized thiopeptide pathways.57 
 
 
different structural requirements or limited promiscuity of their enzymes. Nonetheless, based on 
the enzymes combined here, we predict that many other hybrid RiPP combinations will be feasible. 
In summary, chimeric leader peptides appear to be a broadly applicable and effective 
platform for creating hybrid RiPPs. In the cases shown here, the method afforded significant 
product yields (∼1 mg/L of culture for the core peptide without any optimization) and employed a 
standard coexpression plasmid system. Moreover, RiPP enzymes can be chosen even if the 
enzymes act on the same residue. Our approach was successful regardless of native leader peptide 
length (8 vs 60+), its binding affinity (∼5 µ M for ProcA/ProcM vs ∼50 nM for HcaA/HcaF),22, 38 
how it was bound (RRE or non-RRE binding site), or whether the substrate binding site was 
previously known. Further, our approach is amenable to the inclusion of leader-independent 
enzymes. Accordingly, the chimeric leader peptide strategy holds much potential for combinatorial 
RiPP biosynthesis and opens the door for the generation of additional hybrid RiPP compounds. 
 
3.4 Methods 
3.4.1 General methods 
Materials were purchased from Fisher Scientific, Gold Biotechnology, or Sigma-Aldrich 
unless otherwise noted. Tryptone and yeast extract were purchased from Dot Scientific. Restriction 
enzymes (REs), AspN endoprotease, KOD HotStart polymerase, T4 DNA ligase, and 
deoxynucleotides (dNTPs) were purchased from New England Biolabs (NEB). Oligonucleotide 
primers were synthesized by Integrated DNA Technologies (IDT) and are listed in Table 3.2. DNA 
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spin columns were purchased from QIAGEN, and DNA sequencing was performed by ACGT Inc. 
All polymerase chain reactions (PCRs) were conducted on an S1000 thermal cycler (Bio-Rad).  
 
3.4.2 Cloning 
Plasmids were constructed using restriction enzymes and DNA ligase or by Gibson 
assembly (GA). For RE cloning, the target gene was amplified with KOD HotStart polymerase, 
and after PCR cleanup using the QIAquick PCR Purification Kit Protocol, the amplicon was 
digested with restriction enzymes for ligation into a similarly digested and purified vector. For 
amplifications which gave more than one product, a gel extraction was performed. Ligations were 
performed with T4 DNA ligase at 23 °C for 1 h (100 ng vector and 3-fold excess insert). For GA, 
the standard protocol was followed with guidance from the NEBuilder Assembly tool 
(nebuilder.neb.com). Inserts were generated using KOD HotStart polymerase and purified as 
above. Vector backbones were linearized using PCR or restriction enzymes and similarly purified.  
Genes for the cyclodehydratase (HcaF and HcaD),22 lanthipeptide synthetase (ProcM and 
NisB/C),58 dehydroalanine reductase (NpnJA),39 and flavoenzyme decarboxylase (MibD)45 were 
cloned previously from their native organisms. All new plasmids used in this study are listed in 
Table 3.3 and were constructed using primers listed in Table 3.2.  
The hybrid peptides were built from HcaA or ProcA precursor peptides through overlap 
extension PCR and initially cloned into a modified pET28 vector with an N-terminal maltose-
binding protein (MBP) affinity tag (pET28-MBP). This intermediate was then used to clone the 
gene encoding MBP-tagged hybrid peptides into Duet vectors or to express and purify the peptide 
for in vitro activity assays. The gene encoding the NisA-derived hybrid peptide was synthesized 
as a gblock (IDT) and was cloned directly into a Duet vector in frame with a His6 tag. Duet vectors 
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pACYCDuet, pCDFDuet, pETDuet, and pRSFDuet were used for coexpression in E. coli (see 
Table 3.3), as has been well established,59 and genes were sequentially cloned into each multiple 
cloning site. To insert the cyclodehydratase HcaF and HcaD genes into a single multiple cloning 
site, the genes were taken together as a single amplicon from pETDuet-HcaF-HcaD. 
 
3.4.3 Site-directed mutagenesis 
Changes to the sequence of hybrid peptides were made with cloned PFU or KOD 
polymerase (a proofreading DNA polymerase isolated from Thermococcus kodakaraensis) and the 
site-directed mutagenesis (SDM) primers in Table 3.2 following the Agilent QuikChange protocol. 
 
3.4.4 In vivo production of modified hybrid peptides 
E. coli BL21(DE3) chemically competent cells were cotransformed with pairs of Duet 
vectors (Table 3.3) and selected with 100 µg/mL ampicillin for pETDuet, 50 µg/mL kanamycin 
for pRSFDuet or pET28, and 34 µg/mL chloramphenicol for pACYCDuet. Initial cultures were 
started from single colonies and grown in 10 mL of Luria−Bertani (LB) broth at 37 °C 
supplemented with appropriate antibiotics for several hours, and then used to inoculate 0.5 or 1 L 
of the same media. Cells were grown to OD600 of ~0.8, put on ice for 10 min, and induced with 
0.6 mM IPTG (isopropyl β-D-1-thiogalactopyranoside) at 22 °C. After 18 h induction, cells were 
harvested at 4000 x g for 15 min at 4 °C, washed with TBS (Tris-buffered saline: 25 mM Tris pH 
8.0, 150 mM NaCl), and centrifuged again at 4000 x g for 10 min at 4 °C. Cell pellets were stored 




3.4.5 Protein expression and purification 
E. coli BL21(DE3) cells were transformed with plasmids containing the genes encoding 
the tagged proteins and selected using appropriate antibiotics. Starter cultures were grown in 10 
mL LB with antibiotics and used to inoculate 1 L of similarly prepared media. After reaching an 
OD600 of ~0.8, cells were induced overnight with IPTG. Next, cells were harvested by 
centrifugation at 4000 x g for 15 min at 4 °C, washed with TBS, and then subjected to 
centrifugation at 4000 x g for 10 min at 4 °C. Cell pellets were stored at −20 °C. Proteins used for 
in vitro assays were purified using affinity chromatography via the MBP or His6 tag. 
MBP-tagged proteins were purified from E. coli cells using amylose resin (NEB). The resin 
was preequilibrated with 5 bed volumes of Buffer A [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% 
(v/v) glycerol, 0.1% (v/v) Triton X-100]. Cell pellets were suspended in Buffer A and sonicated 3 
times for 30 s at 10-13 W using a Misonix MICROSON XL2000 Cell Disruptor with 10 min 
incubations at 4 °C between each 30 s sonication period to prevent sample heating. The lysate was 
clarified by centrifugation at 34000 x g for 1 h on a Sorvall RC 6 plus centrifuge, and the 
supernatant applied to the equilibrated resin, and washed with 10 bed volumes of Buffer B [50 
mM Tris pH 7.5, 400 mM NaCl, 2.5% (v/v) glycerol]. Protein was then eluted using Elution Buffer 
[50 mM Tris pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 10 mM maltose] and collected into 
Amicon Ultra 15 mL Filter centrifugal filters [30 kDa NMWL (Nominal Molecular Weight 
Limit)]. The eluted protein was concentrated and a 10-fold buffer exchange was performed into 
Storage Buffer [50 mM HEPES, 300 mM NaCl, 2.5% (v/v) glycerol] through centrifugation at 
4000 x g. The final protein concentration was calculated from the absorbance at 280 nm 
(NanoDrop 2000 UV-Vis Spectrophotometer) with the predicted protein extinction coefficient 
(http://web.expasy.org/protparam/) and the Bradford assay (Pierce™ Coomassie Protein Assay 
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Kit). All proteins were stored at −80 °C. Note that after initial column loading, all wash and storage 
buffers were supplemented with 1 mM tris-(2-carboxylethyl)-phosphine (TCEP). 
His6-tagged proteins were purified identically to the above protocol except the buffer 
composition differed as follows: Buffer A [50 mM Tris pH 7.5, 500 mM NaCl, 2.5% (v/v) glycerol, 
15 mM imidazole], Buffer B [50 mM Tris pH 7.5, 400 mM NaCl, 2.5% (v/v) glycerol, 30 mM 
imidazole], and Elution Buffer [50 mM Tris pH 7.5, 300 mM NaCl, 2.5% (v/v) glycerol, 250 mM 
imidazole]. 
 
3.4.6 Purification of modified hybrid peptides  
All hybrid peptides except Hyp1.x were MBP-tagged and purified as described above. 
Typically, >20 mg of MBP-tagged peptide (corresponding to >1 mg of core peptide after affinity 
tag removal) was obtained from 1 L of culture. Hyp1.x was expressed as a His6-tagged peptide 
and purified by the following procedure. The harvested cells were resuspended in 25 mL of LanA 
Buffer 1 [6 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 500 mM NaCl, 0.5 
mM imidazole], and lysed by sonication (50% amplitude, 1.0 s pulse, 2.0 s pause, 5 min). The 
sample was subjected to centrifugation (23,700 x g for 30 min at 4 °C) and the supernatant 
containing the His6-tagged peptide was retained for further purification. The His6-tagged peptide 
was then purified by immobilized metal affinity chromatography (IMAC) using 2-4 mL of His60 
Ni Superflow Resin (Clontech). The supernatant was applied to the column and the column was 
washed with 2 column volumes of LanA Buffer 1 followed by 2 column volumes of LanA Buffer 
2 [4 M guanidine hydrochloride, 20 mM NaH2PO4, pH 7.5 at 25 °C, 300 mM NaCl, 30 mM 
imidazole], and then eluted with 3 column volumes of LanA Elution Buffer [4 M guanidine 
hydrochloride, 20 mM Tris, pH 7.5 at 25 °C, 100 mM NaCl, 1 M imidazole]. The elution fractions 
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containing the peptide were desalted by Vydac C4 SPE column and lyophilized and stored at −80 
°C. 
 
3.4.7 In vitro modification assays 
In vitro assays were performed with purified proteins and peptides as described 
previously.22, 39, 45, 60 In general, peptides were supplied at 50 µM. Proteins were present at 5 to 20 
µM and allowed to react for 16 h. Reactions were carried out in synthetase buffer [50 mM Tris pH 
7.5, 125 mM NaCl, 20 mM MgCl2, 1 mM TCEP]. However, assays with the dehydroalanine 
reductase (NpnJA) were performed in 50 mM HEPES pH 7.4 with 1.5 mM NADPH.  
 
3.4.8 MALDI-TOF-MS 
Matrix-assisted laser desorption/ionization time of flight mass spectrometry (MALDI 
TOF-MS) was used to analyze posttranslational modifications based on their characteristic mass 
changes and reactivity towards mild acid or iodoacetamide treatment. Upon in vitro or in vivo 
modification, peptides were digested with a commercial protease (AspN or GluC) following the 
manufacturer’s protocol. Hydrochloric acid (200 mM) or iodoacetamide (20 mM at 8 pH) were 
individually added to an aliquot of the digestion and allowed to react for 1 h in the dark at 22 °C 
except in case if acid hydrolysis of Hyp1.x peptides, the incubation time was 5-15 min. Next, the 
samples were desalted with a ZipTip (Millipore) according to the manufacturer’s instructions and 
eluted into 3.5 µL of 70 % MeCN. Then, 0.5 µL was applied to a MALDI target plate with 1 µL 
of matrix and subsequently mixed until crystallized. The samples were analyzed using a Bruker 
Daltonics UltrafleXtreme MALDI-TOF mass spectrometer in reflector/positive mode. 
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Table 3.2 Primer sequences. Restriction enzyme sites are underlined. F, forward; R, reverse. 
 
Primer Name Primer sequence (5’ to 3’) Purpose 
Hyp1.2 F 
ACA CCC GGT TGT AAA ACA GGA 
GCT CTG TAA GGT TGT AAC ATG 
AAA ACA GCA ACT TGT C 
SDM 
Hyp1.2 R 
GAC AAG TTG CTG TTT TCA TGT 
TAC AAC CTT ACA GAG CTC CTG 
TTT TAC AAC CGG GTG T 
SDM 
Hyp1.3 F 
GT ATT TCG CTA TGT ACA CCC 
GGT TGT AAA GCG TAA GGA GCT 
CTG TAA GGT TGT AAC ATG A 
SDM 
Hyp1.3 R 
TCA TGT TAC AAC CTT ACA GAG 
CTC CTT ACG CTT TAC AAC CGG 
GTG TAC ATA GCG AAA TAC 
SDM 
Hyp2.2 F 
CGG CGG AGG CGT TTC CGG CAT 
CCA AGC GGT GCT GCA C 
SDM 
Hyp2.2 R 
CTT GGA TGC CGG AAA CGC CTC 
CGC CGC TAG CGG CTT CC 
SDM 
Hyp_backbone F 
GCG GCC GCA TAA TGC TTA AGT 
CGA ACA GAA AGT AAT CG 
Amplifying vector backbone 
containing MBP-tagged part-
HcaA leader, HcaD and 
HcaF for gibson ligation 
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Table 3.2 (cont.)  
 
Hyp_backbone R 
CCA ATA CAC AAC ATT ACC AGT 
TTG ATA ATC ATT AAG GTT TAA 
TGA TTG TAG TTC TTG TTG 
Amplifying vector backbone 
containing MBP-tagged 
part-HcaA leader, HcaD and 
HcaF for gibson ligation 
MBP-HcaProcA1.1 
F 
GAT TAT CAA ACT GGT AAT GTT 
GTG TAT TGG GAC TTA GAA AAA 
GAG CAT CGC CAA ACC CTG 
 




GTT CGA CTT AAG CAT TAT GCG 
GCC GCT TAT CAG CAC ACA TTG 
ATA GTA AAA CGG TTA GCA 
Amplifying ProcA1.1 for 
gibson ligation Gibson 
ligation 
Hyp3.1_T12S F 
GTG CAG GGT ACT GCT AAC CGT 




CTT TTA TCA GCA CAC ATT GAT 





G GGT TTT CGC TGT GGT CAG 
GGT A CTG CTA ACC GTT TTA 









CCA GCC ACA CCT TCC AGA TCA 




CTG CTA ACC GTT TTA GCA TCA 




TAC CCT GAC CAC AGC GAA AAC 
CCC CAG CCA CAC CTT CCA GAT 
CAT CAT CAG ACA 
Gibson ligation 
Hyp3.2 F 
GT TTT CGC TGT GGT CAG GGT 




CAT TGA TGC TAA AAC GGT TAG 




CT CCA TCC TAT AGC GCA TTT 




ATT ATG CGG CCG CTT AGC ATG 






gblock sequence synthesized (IDT) for Hyp1.1 (vector backbone, gray; HcaA leader peptide, blue; 













Table 3.3 New plasmids generated for this study. HcaF-HcaD are the thiazoline 
cyclodehydratase, NisB and NisC are a class I lanthipeptide synthetase, and ProcM is the class II 
lanthipeptide synthetase. Constructs for the tailoring enzymes MibD and NpnJA are reported 
elsewhere.39, 45 Abbreviations: MCS, multiple cloning site; MBP, maltose binding protein. The 
entries in italics were made by Dr. Brandon Burkhart from Mitchell laboratory at UIUC. 
 




pCDF-1.1 pCDFDuet (~20-40) His6-Hyp1.1 
pCDF-1.2 pCDFDuet (~20-40) His6-Hyp1.2 
pCDF-1.3 pCDFDuet (~20-40) His6-Hyp1.3 
pET-2.1-FD pETDuet (~40) MBP-Hyp2.1; HcaF-HcaD 
pET-2.2-FD pETDuet (~40) MBP-Hyp2.2; HcaF-HcaD 
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Table 3.3 (cont.)  
pET-3.1-FD pETDuet (~40) MBP-Hyp3.1; HcaF-HcaD 
pET-3.2-FD pETDuet (~40) MBP-Hyp3.2; HcaF-HcaD 
pET-4.1-FD pETDuet (~40) MBP-Hyp4.1; HcaF-HcaD 
pET-4.2-FD pETDuet (~40) MBP-Hyp4.2; HcaF-HcaD 
pACYC-M pACYCDuet (~10) (empty); ProcM 
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Chapter 4: Incorporation of Non-Proteinogenic Amino Acids in class I and II Lantibiotics§ 
 
4.1 Introduction 
The extensive genome sequencing efforts of the past decade have provided unparalleled 
information regarding the potential capacity of organisms to produce highly diverse biologically 
active natural products.1 As mentioned in Chapter 1, RiPPs are a large class of such molecules and 
the lanthipeptides form the largest group among RiPP natural products.2-5 Many lanthipeptides 
possess antimicrobial activity and are called lantibiotics. These cyclic peptides have garnered 
increasing attention with respect to engineering for three main reasons. First, they are ribosomally 
synthesized and hence variants of the precursor peptide can be made with relative ease using 
mutagenesis. Second, the biosynthetic enzymes have been shown to be inherently promiscuous 
facilitating analogue formation. And third, the post-translational modifications, by restricting the 
conformational flexibility, allow for higher chemical stability and tighter and/or more specific 
binding to the natural target, thereby improving the bioavailability and bioactivity.4, 6, 7 
Many efforts have been made to increase the diversity of lantibiotics by site-directed 
mutagenesis to afford variants with substitutions by proteinogenic amino acids.8-17 More recently, 
several studies have also shown the potential of expanding the repertoire of substitutions to non-
proteinogenic amino acids (or unnatural amino acids, UAAs) for a subset of lanthipeptides.18-23 
Prompted by these recent reports, we investigated incorporation of UAAs into the class I 
lanthipeptide nisin and the class II lanthipeptide lacticin 481. The methods described in this chapter 
are complementary to previous attempts and illustrate approaches to ensure both incorporation of 
                                                        
§Reproduced from the manuscript under review titled ‘Incorporation of non-proteinogenic amino acid incorporation 
in class I and II lantibiotics’. 
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the UAAs and full post-translational modification. Like the chimeric leader approach described in 
Chapter 3, this methodology provides a versatile approach for creating new structural scaffolds for 
RiPPs. 
 
4.2 Results and discussion 
4.2.1 Lacticin 481 as model system 
Lacticin 481 was first isolated in the early 1990s from Lactococcus lactis subsp. lactis 
CNRZ 481 and exhibits inhibitory activity against a range of indicator strains.24 It is the 
prototypical member of a large group of natural variants with similar ring topology that includes 
nukacin ISK-1 and members of the salivaricin family.25 These compounds exhibit diverse 
antimicrobial potency, but they all contain the mersacidin-like lipid II binding motif within their 
A-ring (Figure 4.1a).8, 10, 26-28 As mentioned in Chapter 2, during the biosynthesis of lacticin 481, 
the lanthipeptide synthetase LctM performs both dehydrations and cyclizations on its precursor 
peptide LctA (Figure 4.1).29 The enzyme first phosphorylates the Ser/Thr targeted for dehydration, 
and then eliminates the phosphate to produce the dehydro amino acids.30 A separate active site 
catalyzes the addition of Cys residues to the dehydro amino acids.31 In a previous study, our 
laboratory showed that substituting aromatic residues in the C-ring with UAAs using substrates 
containing core peptides prepared by solid-phase peptide synthesis (SPPS) could improve the 
bioactivity of lacticin 481.32 These findings were a good starting point for biological incorporation 
of UAAs at those positions. In this study, we aimed to investigate the factors required for 
successful use of stop codon suppression technology for incorporation on UAAs into lantibiotics. 
In a recent report, our group showed the genetic incorporation of hydroxy-amino acids into 
lantibiotics using the pyrrolysine tRNA synthetase and its cognate tRNA.20 Using that platform,  
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Figure 4.1 a) Biosynthesis of lacticin 481, b) Commonly found PTMs in lanthipeptides, color 
code is as per the residues shown in (a).  
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we herein demonstrate the production of several analogs of lacticin 481 and compare their 
bioactivities with the parent compound. Pyrrolysine tRNA synthetase (PylRS) and its mutants are 
robust and versatile enzymes that have been employed to charge pyl-tRNA with several lysine and 
phenylalanine derivatives.33 We chose the N346A/C346A mutant of the Methanosarcina mazei 
PylRS and its cognate pyl-tRNA to incorporate o-Br-Phe, o-NO2-Phe, m-Br-Phe, and m-CF3-Phe 
at three positions (Trp19, Phe21 and Phe23) of lacticin 481.34-36 pRSFDuet plasmids were prepared 
encoding N-terminally His-tagged LctA mutants containing the amber stop codon at each of these 
positions (W19/F21/F23), LctM, and pyltRNA. These plasmids were used together with the 
previously reported pEVOL plasmid carrying orthogonal translation machinery.36 Since the 
mutant PylRS has low selectivity with respect to Phe and its derivatives, and therefore results in 
background incorporation of Phe in the growing peptide chain, we carried out the co-expressions 
in synthetic media37  lacking Phe. Additionally, to improve the solubility of these analogs Asn15 
in lacticin 481 was mutated to Arg.32 Co-expression of His-tagged-LctA/N15R/TAG mutants, 
LctM, PylRS and pyltRNA was carried out in E. coli BL21(DE3) in synthetic media supplemented 
with the desired non-proteinogenic amino acid. After immobilized metal affinity chromatography 
(IMAC) purification of the peptide, analysis by matrix-assisted laser desorption ionization time-
of-flight mass spectrometry (MALDI-TOF MS) showed the formation of full-length LctA with 
four dehydrations and containing the UAA.   
The incorporation was complete and well-tolerated at all positions for all four Phe 
derivatives tested (for a representative example, see Figure 4.2, all other examples are shown in 
Figures 4.8-4.18 in the Methods section 4.4). Thus, the lacticin 481 production system in E. coli 
was not affected by the expression of the additional machinery required for UAA incorporation 





Figure 4.2 MALDI-TOF mass spectrum of lacticin 481/N15R/Trp19m-CF3Phe produced by 
LctM in E. coli BL21(DE3). The dashed line shows the position of the expected peptide if stop 
codon supression did not occur. 
 
mg/L without optimization. 
Since the first residue of the core peptide is Lys, digestion with endoprotease LysN yielded 
the lacticin 481 analogs, which were tested for bioactivity against L. lactis HP. All mutants were 
active, with five of the mutants slightly more active than lacticin 481: Trp19o-ClPhe, Trp19m-
BrPhe, Trp19o-NO2Phe, Phe21o-NO2Phe and Phe23o-ClPhe (Figure 4.3), similar to previous 
observations with aromatic substitutions at these positions prepared with SPPS.28 The MIC values 
determined were 195 nM for Trp19o-NO2Phe, and 390 nM for Trp19o-ClPhe, Trp19m-BrPhe, 
Phe21o-NO2Phe and Phe23o-ClPhe as was the case for the wt-lacticin 481. The improved agar 





Figure 4.3 Agar diffusion assay of wt-lacticin 481 and its mutants against L. lactis HP. 
 
 
4.2.2 Nisin as model system 
Next, we turned to the class I lantibiotic nisin, which is the best-characterized member of 
the family. It has been employed in the food industry as a food preservative for the last five decades 
and significant bacterial resistance is yet to develop.38 As mentioned in Chapter 3, nisin is 
biosynthesized by two proteins, the dehydratase NisB and cyclase NisC (Figure 4.4). Nisin exerts 
its antimicrobial activity through a highly potent dual mode of action. The A- and B-rings 
recognize and sequester the pyrophosphate moiety of lipid II,39 and the C-, D- and E-rings insert 
into the membrane creating pores.40-42 Despite the high antimicrobial potency and non-toxicity to 
humans, nisin is not employed as a human therapeutic, in part because of its low solubility in water, 




Figure 4.4 Biosynthesis of the class I lantibiotic nisin A. The process is shown as first 
completion of dehydration and then cyclization, but this is not necessarily the case. The cyclization 
catalyzed by NisC is reversible as shown by experiments involving resubjection of modified NisA 
to the cyclization conditions.48 
 
We previously reported the heterologous expression of nisin in E. coli, which opened up 
the possibility to investigate generation of nisin analogs using amber stop codon suppression. 
Taking into account the positions that improved the bioactivity of nisin in previous site-directed 
mutagenesis studies,49 as well as the positions at which degradation has been reported,44 we chose 
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to place amber stop codons at positions encoding Thr2, Ser5 and Met21. Since a previously 
reported nisin mutant (Ile4Val/Ser5Phe/Leu6Gly) is a known inhibitor of Lactococcus lactis that 
overcomes the naturally occurring self- protection mechanism,12 we prepared the same variant but 
with an amber stop codon for mutations at Ser5. Plasmids were constructed encoding the His-
tagged NisA mutants and NisB (in pRSFDuet), NisC and pyltRNA (in pCDFDuet), and the pylRS 
mutant and another copy of pyltRNA (in pEVOL). These plasmids were used for co-expression in 
E. coli BL21(DE3) using synthetic media lacking Phe and supplemented with m-Br-Phe and m-
CF3-Phe. Unfortunately, we observed that the full-length peptide with the unnatural amino acid 
was only partially dehydrated by NisB, and that truncants of the peptide were observed in sizable 
amounts due to incomplete amber codon suppression. As a control, we also expressed wild type 
(wt) NisA under these conditions and observed that it also was incompletely dehydrated by NisB 
(see Figure 4.19 in the Methods section 4.4), indicating that the incomplete dehydration is not the 
result of the UAA substitutions. We investigated whether the level of NisB expression was 
insufficient and switched the media to LB, which previously led to full dehydration,18 but this 
resulted in substantial decline in stop codon suppression (Figure 4.5). Thus, unlike the observations 
for lacticin 481, where the requirements for stop codon suppression did not affect the lantibiotic 
processing machinery, for nisin the additional burden placed upon the cell requires additional 
optimization of the post-translational modification process. Similar findings were also recently 
reported in another study on incorporation of UAAs into nisin.22 
To improve the activity of NisB in E. coli grown in synthetic media, we expressed multiple 
copies of NisB (up to three) which afforded a mixture of peptides with improved dehydration  
 115 
 
Figure 4.5 MALDI-TOF mass spectrum of His6-NisA-Thr2m-BrPhe modified by NisB and 
NisC in E. coli BL21(DE3) grown in LB. 
 
(see Figure 4.20 in the Methods section 4.4), but the problem of incomplete stop codon suppression 
persisted. While amber stop codons have been widely used for genetic incorporation of UAAs, the 
method in some cases leads to poor incorporation efficiencies and thus lower yield.50-52 This 
inherent problem is thought to arise in part because of competition between Release Factor 1 (RF1) 
and the orthogonal tRNA charged with the UAA during peptide synthesis.53, 54 In prokaryotes, RF1 
is responsible for recognizing the amber stop codon UAG and terminating peptide synthesis.53, 55 
Thus, for an unrestrictive reassignment of the amber codon from a stop signal to an UAA 
incorporating process, deletion of the prfA gene encoding RF1 has been reported by generation of 
an E. coli strain named genomically recoded organism (GRO).56 In GRO, 321 UAG codons were 
replaced by synonymous UAA codons, thereby eliminating the basal need for RF1, and the prfA 
gene could be deleted. The GRO provides significant advantages for incorporating UAAs into 
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proteins by amber suppression.57 To address the problem of truncation of NisA mutants in our 
studies, we decided to use an even more evolved GRO developed by Jewett and coworkers.58 This 
E. coli strain (C321.ΔprfA-T7RNAPΔrneΔompTΔlon) has the T7 polymerase gene inserted and 
the genes for endonuclease (rne) and proteases (ompT and lon) deleted from the genome. These 
mutations are used commonly in recombinant protein expression to increase mRNA stability and 
reduce degradation of heterologous proteins, respectively.59-62 Given cytosolic expression of 
the lanthipeptides in this work, we suspected that the rne and lon mutations could provide benefits. 
Transformation of this strain with the nisin plasmids overcame the problem of NisA truncation. 
Moreover, we could switch to LB media and observed fully-modified full-length nisin analogues 
as the product (Figure 4.6), although the growth rate as well as the cell yields were reduced, 
presumably because of the high antibiotic pressure during cell culture (kanamycin, 
chloramphenicol and spectinomycin were required to maintain plasmids), the number of proteins 
being expressed in this GRO, and the lower temperature at which the strain was employed (30 oC). 
The UAA-containing nisin variants were produced in the range of 0.2-0.5 mg/L prior to leader 




Figure 4.6 MALDI-TOF mass spectrum of NisA-Thr2m-BrPhe modified by NisB and NisC 
in GRO expressing a single copy of nisB grown in LB medium. 
 
 
Because of these low yields, we only tested the Ser5m-BrPhe mutant for bioactivity after 
trypsin digestion, and it was found to have lower activity than wt nisin (Figure 4.7). Very recently, 
Schultz and coworkers reported a different strategy to improve the dehydration of nisin mutants 
containing para-substituted-Phe and Lys derivatives.22 In that study, additional copies of E. coli 
tRNAGlu/GluRS were expressed, and Methanocaldococcus jannaschii tRNATyr/TyrRS or 
Methanosarcina barkeri pyrrolysine tRNAPyl/PylRS were used for incorporation of the non-
proteinogenic amino acid. Our strategy explored a different approach to address the problem of 




Figure 4.7 Agar diffusion assay of wt nisin A (left) and nisin-I4V/Ser5m-BrPhe/L6G (right) 
against L. lactis HP. 
 
4.3 Conclusion 
In summary, we report two different approaches for the production of lantibiotic variants 
containing UAAs depending on the demands of the biosynthetic machinery. This study provides a 
platform for further exploration of bioactivities and stabilities of different lantibiotics including 
nisin. This work also adds to the growing list of examples of incorporation of UAAs into RiPPs 




All oligonucleotides, restriction endonucleases, and DNA polymerases were purchased 
from Integrated DNA Technologies, New England Biolabs or Invitrogen. Media components for 
bacterial cultures were purchased from Difco laboratories. Chemicals were purchased from Fisher 
Scientific or from Aldrich unless noted otherwise. Non-canonical amino acids were purchased 
from Chem Impex International. Solvents commonly used in peptide purification, including 
trifluoroacetic acid (TFA) and acetonitrile, were obtained in RP-HPLC grade or better and used 
directly without further purification. Endoproteinase LysN and trypsin were purchased from Roche 
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Biosciences or Worthington Biosciences. E. coli DH5α was used as host for cloning and plasmid 
isolation, and E. coli BL21 (DE3) or genomically recoded organism (GRO) C321.ΔprfA-
T7RNAPΔrneΔompTΔlon66 were used as a host for co-expression. GRO was obtained from the 
Jewett laboratory at Northwestern University. 
 
4.4.2 General methods 
All polymerase chain reactions (PCR) were carried out on a C1000™ thermal cycler (Bio-
Rad). DNA sequencing was carried out by ACGT Inc. using appropriate primers. Matrix-assisted 
laser desorption/ionization time-of-flight mass spectrometry (MALDI-ToF MS) was carried out 
on an UltrafleXtreme TOF/TOF mass spectrometer (Bruker Daltonics) at Mass Spectrometry 
Facility (UIUC). 
 
4.4.3 Construction of pRSFDuet-1/nisA mutants+nisB and pCDFDuet-1/nisC/pylT 
The amber codon TAG was introduced into nisA/nisB/pRSFDuet-1 at different positions 
of nisA, generating co-expression vectors encoding NisA-T2B, NisA-I4V/S5B/L6G, and NisA-
M21B, where B stands for the amber stop codon. The mutants were generated using QuikChange 
PCR with the nisA/nisB/pRSFDuet-1 vector as the template.18 The primer sequences are listed in 
Table 4.1. The PCR mixture included 1× Phusion HF buffer 67, dNTP mixture (2 mM each), 
primers (stock solution 100 µM each, final concentration 1 µM each), DMSO (2%, v/v), template 
plasmid nisA/nisB/pRSFDuet-1 (~ 40 ng) and Phusion High-Fidelity DNA Polymerase (0.02 
U/µL). The PCR amplification was performed by twenty five cycles of denaturing (98 °C for 10 
s), annealing (57.5 °C for 30 s), and extending (72 °C for 150 s). The product pNisA1.x (Table 
4.3) was purified by QIA quick PCR Purification Kit (QIAGEN). The purified PCR product was 
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mixed with 2 µL of 10x NEBuffer 4 and 2 µL of DpnI (stock solution 20,000 U/mL, New England 
Biolabs), followed by incubation at 37 °C for 1 h. DpnI was heat-inactivated by incubation at 80 
°C for 20 min. A 5 µL aliquot of the resulting solution was used for heat shock transformation of 
E. coli DH5a.  
One copy of nisC was inserted between BglII and XhoI restriction sites into the MCS2 of 
pCDFDuet-1 via PCR amplification, digestion, and ligation using nisC/pACYCDuet-118 as the 
PCR template. In order to raise the copy number of MmPylT expressed in the host cells, one copy 
of Mmpyrrolysyl-tRNA (pylT) was introduced between BamHI and NotI restriction sites into the 
MCS1 of the constructed nisC/pCDFDuet-1 using the the pEVOL-pylT-mmPylRS(2X)-
N346A/C348A vector as the PCR template, resulting in pNisTC (Table 4.3). The primer sequences 
are listed in Table 4.1.  
A copy of nisB with E. coli-optimized codons was inserted into MCS2 of pNisTC after the 
nisC gene separated by ribosome binding site (rbs) via PCR amplification using appropriate 
primers and then Gibson ligated using the vendor’s protocol to arrive at pNisTCB plasmid. An 
additional copy of nisB was inserted in a similar fashion after the first copy of nisB gene separated 
by a rbs to produce pNisTCBB. 
 
Table 4.1 Sequences of oligonucleotide primers used to prepare analogs of nisin. 
Primer Name Primer Sequence (5'-3') 
proK_BamHI_FP  ATA ATA TGG GAT CCG TGT GCT TCT CAA ATG CCT 
GAG GCC  
tRNA_NotI_RP  ATA ATA TGG CGG CCG CCA TGC AAA AAA GCC 
TGC TCG TTG  
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Table 4.1 (cont.)  
NisA_T2B_FP  CAG GTG CAT CAC CAC GCA TTT AGA GTA TTT 
CGC TAT G  
NisA_T2B_QRP  GCG TGG TGA TGC ACC TGA ATC TTT CTT CG  
NisA_M21B_FP  GAG CTC TGA TGG GTT GTA ACT AGA AAA CAG 
CAA CTT G  
NisA_M21B_QRP  GTT ACA ACC CAT CAG AGC TCC TGT TTT ACA 
ACC  
NisC_T7_PacI_FP  TCC AGG CAT TAA TTA ACG AAA TTA ATA CGA CTC 
ACT ATA GGG G  




GAT TTT TTG AAA GGA GGG AAG AGG AAA TGA 
AGG AGA TAT ACC ATG ATC AAA AGC TCC TTT 




GCG GTG GCA GCA GCC TAG GTT AAT TAA TTA 
TTT CAT ATA TTC TTC GCT CAC AAA CAG ACG 
NisBend/RBS/NisB/Fgib 
 
TTC GGA AGA ATA CAT GAA ATG AAG GAG ATA 
TAC CAT GAT AAA AAG TTC ATT TAA AGC TCA 
ACC G 
pCDF/PacI/NisB/Rgib GCG GTG GCA GCA GCC TAG GTT AAT TAA TCA 
TTT CAT GTA TTC TTC CGA AAC AAA C 
 122 
4.4.4 Construction of pRSFDuet-1/lctA mutants+lctM+pylT 
The amber codon TAG was introduced into histagged-lctA(wt)/lctM/pylT/pRSFDuet-1 at 
different positions of lctA, generating co-expression vectors encoding LctA-W19B, LctA-F21B, 
and LctA-F23B, where B stands for the amino acid to be introduced via the amber stop codon. The 
mutants were generated using QuikChange PCR with the histagged-
lctA(wt)/lctM/pylT/pRSFDuet-120 vector as the template. The primer sequences are listed in Table 
4.2. To improve solubility of these peptides,32, 68 the N15R mutation was introduced via 
QuikChange PCR.  
 
Table 4.2 Oligonucleotide sequences of primers used for preparing analogs of lacticin 481. 
Primer Name Primer Sequence (5'-3') 
LctA_Trp19Stop_N15R_FP CA ATT TCT CAT GAA TGT CGC ATG AAT AGC TAG CAA 
TTT G 
LctA_Trp19Stop_N15R_RP CAA ATT GCT AGC TAT TCA TGC GAC ATT CAT GAG 
AAA TTG 
LctA_F21Stop_FP* ATG AAT AGC TGG CAA TAG GTA TTT ACT TGC TGC 
LctA_F21Stop_RP* GCA GCA AGT AAA TAC CTA TTG CCA GCT ATT C 
LctA_Phe23Stop_FP* AGC TGG CAA TTT GTA TAG ACT TGC TGC TC 
LctA_Phe23Stop_RP* GAG CAG CAA GTC TAT ACA AAT TGC CAG C 
LctA_N15R_FP_new CA ATT TCT CAT GAA TGT CGC ATG AAT AGC TGG C 




4.4.5 Heterologous production, purification, and characterization of lacticin 481 analogs 
The lacticin 481 analogs were expressed using E. coli BL21 (DE3) cells transformed with 
pLctAMx, and pMmPyl (Table 4.3). An overnight culture of these cells was added to a culture 
flask containing synthetic media37 lacking Phe, and containing kanamycin (25 mg/mL) and 
chloramphenicol (12.5 mg/mL). The culture was then incubated in a 37 ºC shaker (220 rpm) until 
the optical density reached 1.0. After cooling at 4 ºC for 15 min, overexpression was induced with 
arabinose (0.2% final concentration) and isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.25 mM 
final concentration) in the presence of non-proteinogenic acid (2 mM final concentration; 
dissolved using appropriate amount of 1 M NaOH right before use), and the flask was incubated 
for 12 h in a shaker at 37 ºC and 220 rpm. The following morning the cells were harvested by 
centrifugation (11,867 ×g, 4 ºC, 20 min), the supernatant was discarded and the cells were lysed 
using a cell homogenizer (Avestin Emulsiflex-C3; 5,000 PSI) in LanA start buffer (2 mL per 100 
mL culture; 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). The 
soluble and insoluble fractions were then separated by centrifugation (22,789 ×g, 4 °C, 20 min) 
and the soluble fraction was saved for purification. The insoluble fraction was suspended in LanA 
lysis buffer (1 mL per 100 mL culture; 6 M guanidine-HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 
mM imidazole, pH 7.5) and the suspension was sonicated. The soluble and insoluble fractions 
were again separated by centrifugation (22,789 ×g, 4 °C, 20 min) and the modified His6-LanA 
peptide was purified from the combined soluble layers using a Ni HisTrap HP column (5 mL, GE 
Healthcare). The column was washed with LanA wash buffer (4 M guanidine-HCl, 20 mM 
NaH2PO4, 500 mM NaCl, 30 mM imidazole, pH 7.5) to remove nonspecific binding proteins. The 
His6-LanA peptide was eluted with LanA elute buffer (3 × 5 mL, 4 M guanidine-HCl, 20 mM 
NaH2PO4, 100 mM NaCl, 500 mM imidazole, pH 7.5). Finally, the peptide solution was desalted  
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by C4 SPE column (Grace Vydac). 
 
4.4.6 Proteolysis of full-length His-tagged modified LctA mutants, and purification of lacticin 
481 analogs  
After solid phase extraction, the full-length peptides were purified further on a C5 
Phenomenex column in a Shimadzu Prep-HPLC Instrument and were observed to elute in a time 
range of 22-25 min when the gradient was set from 2% solvent B to 100%A (solvent A = 0.1% 
TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) over a time period of 45.0 min 
at a flow rate of 7.0 mL /min. Lacticin 481 analogues were obtained via the proteolytic removal of 
the leader peptide using the endoproteinase LysN. The full-length peptides were dissolved in 
water, and incubated in 50 mM Tris buffer (pH 8.0), followed by the addition of LysN at a 
concentration of 1:100 (w/w) with respect to the peptide and incubated overnight at room 
temperature. Extent of cleavage was monitored using MALDI-TOF MS. The peptides were then 
purified using a C18-Phenomenex column in a Agilent Analytical HPLC Instrument and were 
observed to elute in a time range of 23-26 min when the gradient was set from 2% solvent B to 
100%A (solvent A = 0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) 
over a time period of 45.0 min at a flow rate of 1.0 mL /min. 
 
4.4.7 Heterologous production, purification, and characterization of nisin analogues using E. 
coli BL21 (DE3)  
The nisin analogs were expressed using E. coli BL21 (DE3) cells transformed with 
pNisABx, pMmPyl, and either pNisTC or pNisTCB or pNisTCBB (Table 4.3). 
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An overnight culture of E. coli BL21 (DE3) cells was added to a culture flask containing 
synthetic media37 lacking Phe, and containing kanamycin (17 mg/mL), chloramphenicol (10 
mg/mL) and spectinomycin (17 mg/mL). The culture was then incubated in a 37 ºC shaker (220 
rpm) until the optical density reached 1.0. After cooling at 4 ºC for 15 min, overexpression was 
induced with arabinose (0.2% final concentration) and isopropyl β-D-1-thiogalactopyranoside 
(IPTG, 0.25 mM final concentration) and the flask was incubated for 16 h in a shaker at 18 ºC and 
220 rpm. The following morning the cells were harvested by centrifugation (11,867 ×g, 4 ºC, 20 
min), the supernatant was discarded, and the cells were lysed using a cell homogenizer (Avestin 
Emulsiflex-C3; 5,000 PSI) in LanA start buffer (2 mL per 100 mL culture; 20 mM NaH2PO4, 500 
mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). The soluble and insoluble layers were then 
separated by centrifugation (22,789 ×g, 4 °C, 20 min) and the soluble layer was saved for 
purification. The insoluble layer was suspended in LanA lysis buffer (1 mL per 100 mL culture; 6 
M guanidine-HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 7.5) and the 
suspension was sonicated. The soluble and insoluble layers were again separated by centrifugation 
(22,789 ×g, 4 °C, 20 min) and the modified His6-LanA peptide was purified from the combined 
soluble layers using a Ni HisTrap HP column (5 mL, GE Healthcare). The column was washed 
with LanA wash buffer (4 M guanidine-HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 mM imidazole, 
pH 7.5) to remove nonspecific binding proteins. The His6-LanA peptide was eluted with LanA 
elute buffer (3 × 5 mL, 4 M guanidine-HCl, 20 mM NaH2PO4, 100 mM NaCl, 500 mM imidazole, 
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4.4.8 Heterologous production, purification, and characterization of nisin analogues using 
GRO 
The nisin analogues were expressed using GRO transformed with pNisABx, pMmPyl and 
pNisTC (Table 4.3). This strain was always maintained at temperatures below 32 ºC (mostly 30 
ºC) to avoid triggering lambda-red mediated mutagenesis.66, 69  
An overnight culture of E. coli BL21 (DE3) cells was added to a culture flask containing 
LB media containing kanamycin (17 mg/mL), chloramphenicol (10 mg/mL) and spectinomycin 
(17 mg/mL). The culture was then incubated in a 30 ºC shaker (220 rpm) until the optical density 
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reached 0.8. After cooling at 4 ºC for 15 min, overexpression was induced with arabinose (0.2% 
final concentration) and isopropyl β-D-1-thiogalactopyranoside (IPTG, 0.4 mM final 
concentration) in the presence of non-proteinogenic acid (4 mM final concentration; dissolved 
using an appropriate amount of 1 M NaOH right before use) and the flask was incubated for 20 h 
in a shaker at 18 ºC and 220 rpm. The following morning the cells were harvested by centrifugation 
(11,867 ×g, 4 ºC, 20 min), the supernatant was discarded and the cells were lysed using a cell 
homogenizer (Avestin Emulsiflex-C3; 5,000 PSI) in LanA start buffer (2 mL per 100 mL culture; 
20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, 20% glycerol, pH 7.5). The soluble and 
insoluble fractions were then separated by centrifugation (22,789 ×g, 4 °C, 20 min) and the soluble 
layer was saved for purification. The insoluble fraction was suspended in LanA lysis buffer (1 mL 
per 100 mL culture; 6 M guanidine-HCl, 20 mM NaH2PO4, 500 mM NaCl, 0.5 mM imidazole, pH 
7.5) and the suspension was sonicated. The soluble and insoluble layers were again separated by 
centrifugation (22,789 ×g, 4 °C, 20 min) and the modified His6-LanA peptide was purified from 
the combined soluble layers using a Ni HisTrap HP column (5 mL, GE Healthcare). The column 
was washed with LanA wash buffer (4 M guanidine-HCl, 20 mM NaH2PO4, 500 mM NaCl, 30 
mM imidazole, pH 7.5) to remove nonspecific binding proteins. The His6-LanA peptide was eluted 
with LanA elute buffer (3 × 5 mL, 4 M guanidine-HCl, 20 mM NaH2PO4, 100 mM NaCl, 500 
mM imidazole, pH 7.5). Finally, the peptide solution was desalted by using a C4 SPE column 
(Grace Vydac). 
 
4.4.9 Proteolysis of full-length His-tagged NisA mutants, and purification of nisin analogues 
After solid phase extraction, the full-length peptides were purified further on a C5-
Phenomenex column using a Shimadzu Prep-HPLC Instrument and were observed to elute in a 
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time range of 23-25 min when the gradient was set from 2% solvent B to 100% A (solvent A = 
0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) over a time period of 
45.0 min at a flow rate of 7.0 mL /min. Nisin analogues were obtained via the proteolytic removal 
of the leader peptide using the endoproteinase trypsin. The full-length peptides were dissolved in 
water, and incubated in 50 mM Tris buffer (pH 8.0), followed by the addition of trypsin at a 
concentration of 1:100 (w/w) with respect to the peptide and incubated for 3 h at room temperature. 
The extent of cleavage was monitored using MALDI-TOF MS. The peptides were then purified 
using a C18-Phenomenex column in an Agilent Analytical HPLC Instrument and were observed 
to elute in a time range of 22-24 min when the gradient was set from 2% solvent B to 100% A 
(solvent A = 0.1% TFA in water, solvent B = 0.0866% TFA in 80% ACN/20% water) over a time 
period of 45.0 min at a flow rate of 1.0 mL /min. 
 
4.4.10 Agar diffusion growth inhibition assay of lacticin 481, nisin and analogues 
HPLC-purified peptides were dissolved in water, lyophilized and redissolved in water. 
Isolation of authentic lacticin 481 has been described previously.20 For lacticin 481 bioactivity 
assays, overnight cultures of L. lactis HP were diluted in M-17 agar containing 0.5 % glucose to 
an OD600 of 0.05.  The concentrations of the peptide solutions were determined on Agilent 
Analytical HPLC Instrument by measuring their absorbance at 220 nm and then comparing that to 
absorbance of solution of wt-lacticin 481 of known concentration. A total of 10 µL of 12.5 µM 
solution was spotted. The plates were incubated at 30 ºC for 20 h. 
For nisin bioactivity assays, overnight cultures of L. lactis HP were diluted in M-17 agar 
containing 0.5% glucose to an OD600 of 0.05.  A total of 10 µL of 5 µM commercial, HPLC-
purified nisin and analogues was spotted. The plates were incubated at 30 ºC for 18 h. 
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4.4.11 Determination of MIC and IC50 values against liquid cultures of L. lactis HP  
Ninety-six well microtiter plates were used to determine MIC and IC50 values. A total 
volume of culture in each well was 100 µL; the experimental wells contained 15 µL of diluted 
peptide at defined concentrations and 85 µL of a culture of L. lactis HP indicator strain (OD600 = 
0.9 – 1.0) in GM17 medium (M17 media with 2% glucose) diluted 1-to-10 in fresh liquid GM17 
medium. The peptide concentrations ranged from 25 µM to 11.9 nM. Each plate contained two 
lanes for controls: 85 µL fresh GM17 medium and 15 µL sterile Millipore water, and 85 µL of 
untreated 1-in-10 diluted culture and 15 µL sterile Millipore water. The optical density at 600 nm 
(OD600) was recorded at hourly intervals from 0 to 5 h with an additional measurement at 18 h 
using a BioTek Synergy 2 plate reader. Plates were incubated at 30 ºC between readings. The MIC 
values reported are the concentrations where no growth was observed after 18 h.  
Blanks (growth medium and sterile Millipore water only) were averaged and then 
subtracted from the averages of triplicate experimental readings. Growth curves vs. peptide 
concentration were developed, and curve fits for IC50 determination were produced by fitting data 
with OriginPro 8 software using the dose-response curve. IC50 values were calculated from this 
fit. The fitted curves are shown in Figure 4.24. 
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Mass spectra for the eleven lacticin 481 analogs are shown below. For calculated and observed 
masses, see Table 4.4. 
 
Figure 4.8 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/W19o-ClPhe modified by 






Figure 4.9 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/W19m-BrPhe, modified 




Figure 4.10 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/W19o-NO2Phe, 








Figure 4.11 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F21m-BrPhe, modified 




Figure 4.12 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F21m-CF3Phe, modified 











Figure 4.13 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F21o-ClPhe, modified 




Figure 4.14 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F21o-NO2Phe, modified 











Figure 4.15 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F23m-BrPhe, modified 





Figure 4.16 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F23m-CF3Phe, modified 










Figure 4.17 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F23o-ClPhe, modified 





Figure 4.18 MALDI-TOF mass spectrum of His-tagged-LctA-N15R/F23o-NO2Phe, modified 
by LctM in E. coli BL21(DE3). 
 
 
Table 4.4 Masses observed in MALDI-TOF mass spectra of LctA mutants after purification 
of fully modified full-length peptides. 
 
Mutant Mass calculated for 
[M+H]+ peak 




















































Figure 4.19 MALDI-TOF mass spectrum of wild type NisA modified by NisB and NisC in E. 
coli BL21(DE3) in synthetic media at 18 °C. Although the desired 7- and 8-fold dehydrated 
peptides are present, peptides that are dehydrated to a lesser extent are prevalent. m/z calculated 
for [M+H]+ peak for 7-fold dehydrated His-tagged-NisA = 7319.45, m/z observed for [M+H]+ 
peak for the labeled 7-fold dehydrated His-tagged-NisA = 7319. 
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Figure 4.20 MALDI-TOF mass spectra of NisA-Thr2m-BrPhe modified by NisB and NisC in 
E. coli BL21(DE3) in synthetic media with multiple copies of nisB gene expressed. 
 
 
Mass spectra for the three modified NisA analogs are shown below. 
 
Figure 4.21 MALDI-TOF mass spectrum of NisA-I4V/S5B/L6G with S5 substituted by m-




Figure 4.22 MALDI-TOF mass spectrum of NisA-I4V/S5B/L6G with S5 substituted by m-










Figure 4.23 MALDI-TOF mass spectrum of NisA-M21/m-BrPhe, modified by NisB and NisC 
in GRO. The peptide was expresed in very low yields.  
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Table 4.5. Masses observed in MALDI-TOF mass spectra of NisA mutants after purification 
of full-length peptides expressed in GRO. 
 
Mutant Mass calculated for the 
major peak, [M+H]+  
Mass observed for the 
major peak, [M+H]+ 
His-tagged-NisA-T2m-BrPhe (Fig. 

















Figure 4.24 IC50 fitting curves for wt-lacticin 481 and five analogs that were found to be more 
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